UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-KSB
Annual Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|
|
|
|
|
For the fiscal year ended September 30, 2008
|
|
Commission file number 1-11700
|
HEMAGEN DIAGNOSTICS, INC.
(Name of Small Business Issuer in Its Charter)
|
|
|
|
|
Delaware
|
|
04-2869857
|
|
(State or other jurisdiction
of incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
9033 Red Branch Rd., Columbia, MD 21045
(Address of Principal Executive Offices) (Zip Code)
(443) 367-5500
(Issuer’s telephone number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common Stock.
Check whether
the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.
¨
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 60 days. Yes
x
No
¨
.
Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this
form, and will no disclosure be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB.
¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2
of the Exchange Act).
¨
The registrant had revenues of $6,374,799 from
continuing operations in its most recent year. The aggregate market value of the voting stock held by non-affiliates of the registrant on December 16, 2008, was $1,220,348. As of December 16, 2008, 15,225,289 shares Common Stock were outstanding.
HEMAGEN DIAGNOSTICS, INC.
INDEX TO ANNUAL REPORT ON FORM 10-KSB
Table of Contents
Certain statements contained in this report that are not historical facts constitute
forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Forward looking statements may be identified by words such as
“estimates”, “anticipates”, “projects”, “plans”, “expects”, “intends”, “believes”, “should” and similar expressions or the negative versions thereof and by the context
in which they are used. Such statements, whether express or implied, are based on current expectations of the company and speak only as of the date made. Reliance should not be placed on forward-looking statements because they involve known and
unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied. Hemagen undertakes no obligation to update any forward-looking statements as a result of
new information or to reflect events or circumstances after the date on which they are made.
Statements concerning the
establishments of reserves and adjustments for dated and obsolete products, expected financial performance, on-going business strategies and possible future action which Hemagen intends to pursue to achieve strategic objectives constitute
forward-looking information. All forward looking statements, including those relating to the sufficiency of such charges, implementation of strategies and the achievement of financial performance are each subject to numerous conditions,
uncertainties, risks and other factors. Factors which could cause actual performance to differ materially from these forward-looking statements, include, without limitation, management’s analysis of Hemagen’s assets, liabilities and
operations, the failure to sell date–sensitive inventory prior to its expiration, competition, new product development by competitors which could render particular products obsolete, the inability to develop or acquire and successfully
introduce new products or improvements of existing products, costs and difficulties in complying with the laws and regulations administered by the United States Food and Drug Administration, changes in the relative strength of the U.S. dollar and
Brazilian reais, unfavorable political or economic developments in Brazilian operations, and the ability to assimilate successfully product acquisitions.
2
PART I
|
Item 1.
|
Description of Business.
|
Hemagen Diagnostics, Inc. is a biotechnology company that develops, manufactures, and markets approximately 68 FDA-cleared proprietary medical diagnostic test kits and components. There are two
different product lines, the Virgo
®
line and the Analyst
®
line. The Virgo
®
product line consist of various diagnostic test kits that are used to aid in the diagnosis of certain autoimmune and infectious diseases, using ELISA, Immunoflourescence, and hemagglutination technology. The Analyst
®
product line is an FDA-cleared Benchtop Clinical Chemistry Analyzer System, including consumables that are used to measure important constituents in human and animal blood. The Company was
incorporated in 1985 and became a public company in 1993. Hemagen’s principal offices are located at 9033 Red Branch Road, Columbia, Maryland 21045 and the telephone number is (443) 367-5500. Hemagen maintains a website at
www.hemagen.com
. Investors can obtain copies of our filings with the Securities and Exchange Commission from our site free of charge as well as from the Securities and Exchange Commission website at www.sec.gov.
In September 1998, The Company acquired the Analyst
®
Benchtop Clinical Chemistry System, which was originally designed by Dupont, from Dade Behring, Inc. The Analyst
®
is a proprietary bench top clinical
chemistry instrument and reagent system. The Analyst
®
instrument is used to test general chemistry profiles for both the human and veterinary markets using a proprietary consumable rotor
that is manufactured by Hemagen at its Columbia, Maryland facility. The Analyst
®
is cleared by the FDA for marketing in the United States to physician office laboratories. In December 2002
Hemagen also acquired another veterinary chemistry analyzer system, the Endocheck. Today, Hemagen estimates that its customer base for the Analyst
®
is approximately 90% veterinary practices
and 10% physician office laboratory practices.
In 1995, Hemagen completed the
acquisition of a comprehensive line of diagnostic test kits utilizing immunofluorescence technology (“IFA products”) from Schiaparelli Biosystems, Inc. The IFA products and Hemagen’s comprehensive line of proprietary diagnostic test
kits based on enzyme-linked immunosorbence assay technologies (“ELISA” or “EIA”) and hemagglutination technology (“HA”) form the Virgo
®
product line. These
products are used to test for autoimmune and infectious diseases and are manufactured for manual use or for use on automated instrument platforms.
The Virgo product-line is marketed directly to reference laboratories, hospitals, and universities
in the United States, among others and internationally. There are over 30 distributors that market the Virgo
®
product line. Hemagen also markets the Virgo
®
product line in South America through its wholly-owned subsidiary Hemagen Diagnosticos Comercio, Importacao Exportacao, Ltd. (HDC), a Brazilian limited liability company.
Recent Developments
During fiscal
2008 management continued to work toward achieving its goal of increasing shareholder value and achieving sustained profitability. Some of the important steps taken toward achieving those goals were as follows:
|
|
•
|
|
In July 2007, the Company entered into an agreement to sell the assets of its wholly-owned subsidiary Reagents Applications Inc., The sale was consummated on
October 8, 2007. The Company’s decision to sell the assets of Reagents Applications Inc. was made based on careful consideration of an offer received for the business, and in light of the resources required to operating the business, and
the challenges associated with the geographic location and the size of the business. Management also determined that it could better utilize its resources to develop its other product lines.
|
|
|
•
|
|
During fiscal 2008, the Company launched the Analyst
®
III, the redesigned version of the Analyst
®
Benchtop Clinical Chemistry System. The Company began shipping the new unit in September 2007.
|
|
|
•
|
|
During the year the Company also entered into agreements to distribute a hematology analyzer, a compact electrolyte and a blood gas analyzer.
|
3
|
|
•
|
|
The Company launched a line of automated IFA instruments to be placed in large customer labs in Brazil. In conjunction therewith, the Company closed on a lease
line to provide for instruments to be leased with a purchase option. During the year, the Company placed several instruments in key labs and has signed supply contracts with these customers.
|
|
|
•
|
|
During the year, the Company renewed its working capital line with Bay National Bank.
|
|
|
•
|
|
The Company has taken steps to consolidate operations into more compact and efficient space, and has continued to seek out and implement cost reductions.
|
Technology
Analyst Instrument System
Hemagen acquired a
patent protected rotor based technology for use in the Analyst
®
in 1998. The Analyst
®
is a bench-top centrifugal clinical
chemistry analyzer. The Analyst
®
utilizes a consumable rotor that contains dry prepackaged reagents. The Analyst
®
spins the
rotor, mixing the patient sample with the dry reagents, producing a result in approximately ten minutes. Hemagen currently markets four types of rotors providing a variety of clinical chemistry tests which are 510K cleared by the FDA for the human
medical market and two types of rotors that are exclusively sold for the veterinary market. The Analyst
®
instrument has been designated by the Clinical Laboratory Improvements Amendments
(CLIA) as a moderately complex system, and is therefore suitable for both the physician and veterinary office laboratories. Hemagen’s blood chemistry and Analyst
®
system assays are
used to aid in the monitoring and measurement of health profiles, such as cholesterol, blood urea nitrogen, triglycerides, glucose and uric acid.
During fiscal 2008, the Company launched the Analyst
®
III, the redesigned version of the Analyst
®
Benchtop Clinical Chemistry System. The company signed a Development Agreement with a third party to redesign
the instrument based on the Analyst
®
technology, and the instrument is being manufactured by the third party under a supply agreement.
In addition, Hemagen has entered into agreements to distribute a hematology analyzer and an
electrolyte and blood gas analyzer to complement the Analyst
®
.
Autoimmune and Infectious Disease Assays
Detection of the presence and concentration of certain antibodies in human blood
can assist physicians in the diagnosis of certain diseases. Hemagen’s assays are
in vitro
(outside of a patient’s body) diagnostic tests that are used to measure specific substances, antibodies, in blood or other body fluids. Our
assays recognize specific antibodies that bind to our assay platforms in the proper environment, making it detectable either by the naked eye, or with the aid of a laboratory technique, which amplifies the reaction so that it is rendered visible.
Hemagen’s hemagglutination, ELISA and immunofluorescence assays are three examples of such techniques.
Immunofluorescence
Hemagen’s immunofluorescence tests are manufactured using several procedures with the most common
being mammalian cells grown on microscope slides treated with disease-producing organisms (viral or bacterial). Serum from a patient is placed in contact with the infected cells on the slides. If a patient has antibodies to the organism causing the
disease, the antibodies will bind to the organism. A chemical reagent is added to the slide that binds to the organism and the antibody, if present and detectable. When the slide is illuminated with light at a specific wavelength in a fluorescent
microscope, the chemically-treated cells will appear with a specific fluorescent pattern, indicating a positive test result. If the patient does not have detectable quantities of the appropriate antibody, no fluorescence will appear producing a
negative test result.
Enzyme Linked Immunosorbent Assays
ELISA or EIA tests employ small plastic wells coated with particular antigens. The test process involves introducing the patient’s serum into the well to allow a reaction to occur. If the
antibody being tested for is present, it will bind to the antigens on the inner surface of the well. After the wells are rinsed, the specifically bound antibody will remain while any non-specific antibodies will be washed away. To detect the
quantity of the specific antibody, other compounds (conjugate, substrate) are added which will cause a color change in the liquid, the intensity of which is proportionate to the quantity of the specific antibody found. If no color is noted, this
indicates that the patient’s serum did not contain detectable quantities of the specific antibody.
4
Hemagen has developed an application for its ELISA technology to detect cardiovascular and inflammatory
risk factors (apolipoproteins) and inflammatory signals (acute phase reactants), the latter of which are present in a patient’s blood prior to the clinical manifestation of infection or inflammation. If successful, these technologies could lead
to earlier detection and prevention of cardiovascular disease, the imminent rejection of transplanted organs or the onset of infections. Such earlier detection could enable physicians to better plan appropriate treatment of patients with these
conditions. Hemagen currently markets two test kits to detect inflammatory signals.
Hemagglutination
Hemagglutination is the agglutination or “clumping” of red blood cells (RBCs). Many substances, including certain antibodies, when placed in
contact with RBCs, will cause agglutination. Under the appropriate conditions, human RBCs may be modified or sensitized by binding specific foreign antigens to their surface. These sensitized RBCs will bind to the specific antibody and this will
cause agglutination of these cells. The presence of certain antibodies in an individual’s serum (blood from which clotted RBCs have been removed) can indicate certain diseases. By sensitizing RBCs with an antigen that specifically reacts with a
particular antibody, the simple visible observation of the agglutination reaction will indicate the presence of the disease-produced antibody. The use of RBCs instead of other particles can allow for simple visual observation of the agglutination
reaction in the proper environment, and reduces the non-specific reactions seen in artificial systems such as those that utilize latex particles.
To perform Hemagen’s hemagglutination test, a technician combines Hemagen’s sensitized RBCs with a patient’s serum in a small well with a V-shaped bottom according to directions included with Hemagen’s test kits. If no
agglutination takes place, the RBCs will settle to the bottom of the well, resulting in a clearly visible red dot which indicates that the test is negative. In contrast, if the particular antibody is present in the patient’s blood, the RBCs
will agglutinate, which prevents the RBCs from settling to the bottom of the well. Instead of the small red dot, the substance will appear a diffuse red, which indicates a positive reaction.
Current Products
Analyst
®
System Products
Hemagen currently markets four FDA 510(k) cleared rotor types for use on the Analyst
®
clinical chemistry analyzer, two general chemistry rotors, a glucose
test and a lipid screen test. In addition, Hemagen sells four rotors specifically designed for the veterinary marketplace: VET-16, VetFlex7, VetFlex and T4 rotors.
Immunofluorescence or “IFA” Products
Hemagen’s
immunofluorescence products consist primarily of diagnostic assays for infectious diseases and several products for autoimmune diseases. Immunofluorescence kits are used as primary or confirmatory tests in many large clinical laboratories worldwide.
There are currently 15 kits sold in the immunofluorescence format.
Hemagen’s immunofluorescence products are used to aid in the
diagnosis of the following diseases:
|
|
|
|
|
Cytomegalovirus
|
|
Herpes simplex
|
|
SLE (Lupus)
|
|
German Measles
|
|
Connective Tissue Diseases
|
|
Chicken Pox
|
|
Primary Bilary Cirrhosis
|
|
Epstein-Barr virus (Mononucleosis)
|
|
Toxoplasmosis
|
|
Chlamydia
|
|
Syphilis
|
|
Measles
|
|
RSV
|
|
Mumps
|
|
|
|
Autoimmune Diseases
|
ELISA Assays
Hemagen develops, manufactures and markets ELISA test kits for the detection of disease. Along with the immunofluorescence and hemagglutination assays, Hemagen’s ELISA kits test for specific
antibodies. The quantitative or semi-quantitative test results give useful information about the stage and prevalence of a particular disease. ELISA tests are widely used by large laboratories, due to
5
their ready adaptability to automation and high volume testing. Hemagen’s autoimmune and infectious disease ELISA kits are used in the diagnosis of the
following diseases:
|
|
|
|
|
Systemic Lupus Erythematous (Lupus)
|
|
Rheumatoid Arthritis
|
|
Scleroderma
|
|
Sjögren’s Syndrome
|
|
Glomerulonephritis
|
|
Mixed Connective Tissue Disease
|
|
Polymyositis
|
|
Dermatomyositis
|
|
Primary Biliary Cirrhosis
|
|
Wegener’s Granulomatosis
|
|
Systemic Vasculitides
|
|
Anti-Phospholipid Syndrome
|
|
Venous and Arterial Thromboses
|
|
Thrombocytopenia
|
|
Recurrent Abortion
|
|
Toxoplasmosis
|
|
Rubella (German Measles)
|
|
Cytomegalovirus Infections
|
|
Herpes simplex
1 & 2 Infections
|
|
Chagas Disease
|
|
Varicella Zoster Infections (Chicken Pox & Shingles)
|
|
|
Hemagen has also developed specialized assays for quantitative analysis of the acute phase
markers, specifically, C-Reactive Protein and Serum Amyloid A. These are believed to be important in the detection and prediction of inflammatory events associated with several diseases, including Systemic Lupus, Rheumatoid Arthritis, and Myocardial
Infarction.
Hemagen also offers ELISA & Hemagglutination screening assays, capable of verifying the presence of as many as six
analytes in a single test. This is a useful tool in a patient’s initial assessment. For example, if an individual’s autoimmune screen 6 test is positive, individual marker kits are then used to differentially diagnose the particular
rheumatoid disease. To better serve customers’ needs, most of the reagents for these kits are offered in both lyophilized and liquid-stable formats.
Hemagglutination Assays
Hemagen’s hemagglutination assays are based on Hemagen’s
proprietary technique to lyophilize, or “freeze dry,” the RBCs which form the central component of a hemagglutination assay. Hemagen’s proprietary lyophilization technique for the preservation of RBCs permits the production of
standardized, easy-to-use and accurate hemagglutination tests with an extended shelf-life, most of which were previously unavailable using hemagglutination assays. The shelf-life of the lyophilized RBCs before reconstitution may be up to 48 months.
A technician reconstitutes the powdered cells in a water-based solution prior to introducing to the patient’s serum.
Each
hemagglutination test also requires a specific formula to sensitize the RBCs prior to lyophilization such that they will react to a specific antibody. For each of its tests, Hemagen uses a proprietary formula to combine antigens and other reagents
with RBCs in a manner that allows for standard, sensitive and specific agglutination reactions. Results from Hemagen’s test kits are generally available within two hours. Hemagen’s hemagglutination test kits aid in the diagnosis of the
following diseases:
|
|
|
|
|
SLE (Lupus)
|
|
Dermatomyositis
|
|
Mixed Connective Tissue Disease
|
|
Polymyositis
|
|
Sjögren’s Syndrome
|
|
Rheumatoid Arthritis
|
|
Scleroderma (Systemic Sclerosis)
|
|
Chagas’ Disease
|
Distribution and Marketing
General
In the United States, Hemagen sells its products directly and through
distributors to clinical laboratories, hospitals, veterinary offices and research organizations, among other places. Internationally, Hemagen sells its products primarily through distributors and its wholly-owned subsidiary in Brazil. Hemagen grants
both exclusive and non-exclusive distributorships, which generally cover limited geographic areas and specific test kits. Hemagen has relationships with over 30 distributors in various countries worldwide.
Hemagen markets its Virgo
®
product
line in South America through its wholly owned subsidiary, Hemagen Diagnosticos Comerico, Importacao e Exportacao, Ltda, (“HDC”) in Sao Paulo, Brazil. Hemagen also engages numerous distributors throughout South America. HDC maintains a
fully staffed sales, marketing, distribution, warehouse and administrative office. In fiscal years 2008, and 2007, Hemagen derived product sales through HDC of $2,494,000 and $1,371,000 respectively, which represents 39% and 31% of Hemagen’s
total sales from continuing operations, respectively.
6
Products Under Development
Hemagen spent approximately $147,000 and $28,000 on research and development for the fiscal years ended September 30, 2008, and 2007, respectively. These numbers do not reflect research and
development costs associated with the discontinued operations. Research and development costs for the discontinued portion of the operation were $2,000 and $271,000 for the fiscal years ended September 30, 2008 and 2007, respectively. Such
research and development is focused on:
|
|
•
|
|
Activities related to upgrades to the Analyst instrument and product offering such as evaluating and developing complimentary products for Hemagen’s Analyst
product line to distribute to the veterinary market and alternative tests utilizing the Analysts’ rotor technology; and
|
|
|
•
|
|
Developing new ELISA kits and enhancing existing ELISA kits.
|
|
|
•
|
|
Developing and enhancing IFA kits
|
Manufacturing and Sources of Supply
Hemagen manufactures its ELISA
test kits, hemagglutination test kits, immunofluorescence test kits and Analyst
®
and Endochek consumables at its Columbia, Maryland facility. The Analyst
®
and the Endochek instruments are manufactured by third parties for Hemagen. Hemagen purchases many of the antigens and other reagents used in its kits from outside vendors. Certain of these antigens and reagents are
from single suppliers. The Company attempts to mitigate such risk from these single suppliers by maintaining an adequate supply of inventory and/or backup suppliers. If the products purchased from these single sources become unavailable there can be
no assurances that the Company will be able to substitute a new supplier in a timely manner and thus could have a material adverse effect on the business, financial condition, and results of operation. Certain reagents used in Hemagen’s test
kits are manufactured at Hemagen’s facilities. Hemagen uses lyophilization equipment to preserve sensitized red blood cells for its hemagglutination test kits. All of Hemagen’s products are manufactured under the Quality System Regulation
as defined by the FDA.
Most components used in Hemagen’s products are
available from multiple sources. The outsourced manufacturing of the Analyst
®
instrument can be obtained from multiple sources while the manufacturing of the Endochek is sole sourced.
Hemagen does not consider the dependence on a sole source for the Endochek a business risk for Hemagen because the Analyst
®
instrument is a viable alternative to the Endochek. The chemistry
tablets that are used in the Analyst
®
rotors are manufactured for the Company pursuant to a manufacturing agreement with another diagnostics manufacturing company that has been a reliable
vendor for the Company for over nine years. This company is a sole source for the tablets today. The Company continues to consider other potential vendors or alternative vendors for tablet manufacturing although there can be no assurances that we
will be able to develop any new suppliers for the chemistry tablets used in the Analyst
®
product line.
Government Regulation
Hemagen’s manufacturing, distribution and marketing of diagnostic
test kits is subject to a number of both domestic and international regulatory controls. In the United States, Hemagen’s production and marketing activities are subject to regulation by the FDA, under the authority of the Federal Food, Drug,
and Cosmetic Act, as amended.
These regulations require that Hemagen must formally notify the FDA of its intentions to market
in
vitro
diagnostic devices through a regulatory submission process, either the 510(k) process or the Pre-market Approval (PMA) process. When a 510(k) process is used, Hemagen is required to demonstrate that the product is “substantially
equivalent” to another product in commercial distribution. Under the 510(k) process, Hemagen cannot proceed with sales of its diagnostic products in the United States until it receives clearance from the FDA in the form of a substantial
equivalency letter. Currently, the majority of products that are reviewed by the 510(k) process are cleared within 90 days. In certain cases, specifically for Class III devices, Hemagen must follow the PMA process that involves a lengthier and more
burdensome process.
7
Hemagen is required to register with the FDA as a device manufacturer and to disclose its devices.
Accordingly, Hemagen is subject to inspection on a routine basis for compliance with the FDA’s Quality System Regulations. These regulations require that Hemagen manufacture its products and maintain its documents in a prescribed manner with
respect to design, manufacturing, testing, process control and distribution activities. In addition, Hemagen is required to comply with various FDA requirements for labeling, pursuant to the applicable regulations. The most recent inspections by the
FDA were in May 2006 for the Columbia, MD facility. The results of those inspections can be reviewed at
www.fda.gov
., the content of which is not incorporated herein. Finally, the FDA prohibits an approved device from being marketed for
unapproved applications. Hemagen believes it is in compliance with all such regulations.
In January 2004, the Company received CE
certification thereby allowing the Company to sell certain of its registered products in the European Community. The Company plans to obtain ISO 13485 certification in order to market additional products in the European Community and Canada.
Competition
The clinical diagnostic industry is highly competitive. There are many companies, both public and private, engaged in diagnostics-related sales, including a number of well-known pharmaceutical and chemical companies. Competition is based
primarily on product reliability, customer service and price. Many of these companies have substantially greater capital resources and have marketing and business organizations that are substantially greater in size than Hemagen. Many companies have
been working on immunodiagnostic reagents and products, including some products believed to be similar to those currently marketed or under development by Hemagen. Hemagen believes that its primary competitors in the market include Abaxis Inc.,
Bion, Bio-Rad Laboratories, Corgenix Medical Corporation, Diamedix Corporation, Heska Corporation, IDEXX Laboratories, Inc., Immco Diagnostics, INOVA Diagnostics, Inc., The Binding Site Ltd. and Trinity Biotech Plc, among others. Hemagen expects
competition within this industry to intensify.
Product Liability
The testing, marketing and sale of clinical diagnostic products entail an inherent risk of allegations of product liability, and there can be no assurance that product liability claims will not
be asserted against Hemagen. Hemagen may incur product liability due to product failure or improper use of products by the user. Inaccurate detection may result in the failure to administer necessary therapeutic drugs or administration of
unnecessary and potentially toxic drugs. Even with proper use of a product, there may be specific instances in which the results obtained from Hemagen’s test kits could lead a physician to predict the inappropriate therapy for a particular
patient. Hemagen maintains product liability insurance in the amount of up to $2,000,000 per incident and in the aggregate which, based on Hemagen’s experience and industry practice, Hemagen believes to be adequate for its present operations.
No assurance can be given that Hemagen’s insurance coverage is sufficient to fully insure against claims which may be made against Hemagen.
Patents and Proprietary Rights
Hemagen protects its technology primarily as trade secrets rather than relying on patents,
either because patent protection is not possible or, in management’s opinion, would be less effective than maintaining secrecy. In addition, Hemagen relies upon confidentiality agreements with its employees. To the extent that it relies on
confidentiality agreements and trade secret protection, there can be no assurance that Hemagen’s efforts to maintain secrecy will be successful or that third parties will not be able to develop the technology independently. In the future,
Hemagen may apply for patent protection for certain of its technologies when management believes such protection would be beneficial to Hemagen. The protection afforded by patents depends upon a variety of factors which may severely limit the value
of the patent protection, particularly in foreign countries, and no assurance can be given that patents, if granted, will provide meaningful protection for Hemagen’s technology.
Employees
As of September 30, 2008, Hemagen had thirty-two full-time
employees and two employees working on a contractual basis. Eighteen employees are in sales, marketing, general and administrative activities and sixteen (including contractual personnel) are involved in production activities.
None of Hemagen’s employees are represented by a labor organization and Hemagen is not a party to any collective bargaining agreement. Hemagen has
never experienced any strike or work stoppage and considers its relationship with its employees to be good.
8
|
Item 2.
|
Description of Property.
|
Hemagen maintains its principal administrative office, laboratory and production operations in a 27,400 square foot leased facility in Columbia, Maryland. The company plans to reduce the space it utilizes in the Columbia, MD facility to
20,100 square feet by June 30, 2009 and has received a commitment from the landlord to subsidize $154,400 in the form of a tenant improvement allowance. Under the Columbia lease, which was recently extended through June 30, 2012, Hemagen
will pay approximately $206,000 per year in rent for the upcoming fiscal year.
Hemagen’s subsidiary, Hemagen Diagnosticos Comercio,
Importacao e Exportacao, Ltd, leases approximately 6,000 square feet of flexible office space in Sao Paulo, Brazil. The lease, which expired on June 30, 2006, has been extended without a definitive stated term. Either party can terminate with
60 days notice. This subsidiary paid approximately $75,000 per year in rent for this space. Management is currently seeking to relocate to a less expensive, and more efficient and effective space.
Management believes that all of the properties are adequately insured.
|
Item 3.
|
Legal Proceedings.
|
Not
applicable.
|
Item 4.
|
Submission of Matters to a Vote of Security Holders.
|
Not applicable.
Part II
|
Item 5.
|
Market for Common Equity and Related Stockholder Matters and Small Business Issuer Purchases of Equity Securities.
|
Hemagen’s Common Stock has been traded on the over-the-counter bulletin board (OTC-BB) market since March 3, 2003 under the symbol
“HMGN.OB.” On November 18, 2008, the closing bid and ask price for the Common Stock as reported by the OTC-BB were $0.05 and $0.18 per share, respectively.
For the periods indicated, the following table sets for the range of high and low bid prices for the Common Stock as reported by the OTC-BB during fiscal 2008 and 2007. These prices reflect inter-dealer prices,
without retail mark-up, mark-down or commission, and may not represent actual transactions.
|
|
|
|
|
|
|
|
|
|
|
High
|
|
Low
|
|
Fiscal 2008
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
0.25
|
|
$
|
0.16
|
|
Second Quarter
|
|
$
|
0.19
|
|
$
|
0.13
|
|
Third Quarter
|
|
$
|
0.25
|
|
$
|
0.11
|
|
Fourth Quarter
|
|
$
|
0.24
|
|
$
|
0.10
|
|
Fiscal 2007
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
0.34
|
|
$
|
0.20
|
|
Second Quarter
|
|
$
|
0.30
|
|
$
|
0.22
|
|
Third Quarter
|
|
$
|
0.26
|
|
$
|
0.19
|
|
Fourth Quarter
|
|
$
|
0.24
|
|
$
|
0.16
|
As of November 21, 2008, there were 168 holders of record of Hemagen’s Common Stock,
which Hemagen believes represents approximately 1,496 beneficial owners.
Dividends
Hemagen has never paid cash dividends. Hemagen currently intends to retain all future earnings, if any, for use in its business and does not anticipate
paying any cash dividends in the foreseeable future.
9
|
Item 6.
|
Management’s Discussion and Analysis or Plan of Operation.
|
Refer to “Forward Looking Statements” following the Index in the front of this Form 10-KSB.
Overview
Historically, Hemagen has concentrated its efforts on developing, manufacturing and
marketing medical diagnostic test kits used to aid in the diagnosis of certain diseases and for assessing general health conditions. Hemagen has approximately 68 different test kits available that are 510(K) cleared for sale in the United States by
the FDA, as well as other products that are not required to be FDA cleared that it sells.
During the year, Hemagen sold the assets of its
wholly-owned subsidiary, Reagents Applications Inc., a clinical chemistry reagent manufacturing business located in San Diego, CA. The sale was consummated on October 8, 2007. The Company’s decision to sell the assets of Reagents
Applications Inc. was made after careful consideration of an offer received for the business, and after considering the resources required to operate the business, the challenges associated with the geographic location, the size of the business and
the opportunity to develop its other product lines.
Management has been working to take the appropriate actions to improve the management
and operations of the Company while striving to achieve sustained profitability. There can be no assurance that any of the previously discussed actions management is taking will achieve the desired results. However, management believes that as a
direct result of these actions, cash flow from operations, the cash on hand at September 30, 2008 and its line of credit availability will be sufficient to finance its operations for fiscal 2009. See the “Recent Developments” section
on page 3.
At September 30, 2008, Hemagen had $98,799 of unrestricted cash, trade accounts receivable (net) of $866,306, a negative
working deficit of $2,225,607 and a current ratio of .6 to 1.0. Included in the calculations of working capital and the current ratio is approximately $3,979,000 of subordinated debt which is due on September 30, 2009. During the upcoming
fiscal year, the company expects to restructure the debt by, among other things, extending the maturity date of the notes representing such debt, but no assurances can be made in this regard. Excluding the subordinated debt in the calculation of
working capital, which assumes that it is restructured successfully, results in working capital of $1,753,393 and a current ratio of 2.1 to 1.0.
Hemagen has a revolving line of credit with a bank for the purpose of financing working capital needs as required. The line of credit facility currently provides for borrowings up to $500,000, at an annual interest rate of the prime rate
plus 3/4%. The line of credit matures on March 31, 2009 and the Company expects to renew the line at that time. Notwithstanding, Hemagen can give no assurances that it will have sufficient cash flow to finance its operations.
Off-Balance Sheet Arrangements
Hemagen has no off-balance sheet arrangements.
Results of Operations
Fiscal Year Ended September 30, 2008 Compared to Fiscal Year Ended September 30, 2007
Revenues from continuing operations for fiscal 2008 increased approximately $1,888,000
(42%) to approximately $6,375,000 from approximately $4,487,000 for fiscal 2007. The overall increase in sales resulted from approximately $878,000 of increased sales in the Company’s Analyst
®
Equipment, an increase of approximately $1,046,000 in the Company’s autoimmune and infectious disease line, and a decrease of approximately $45,000 in the Company’s Endocheck product line.
Sales of the Analyst
®
Clinical
Chemistry Analyzer product line were $878,000 higher than the prior year due to the launch of the new Analyst
®
III Clinical Chemistry Analyzer line during the last quarter of 2007. The
Company expects to see increased growth in revenue as a result of increased Analyst
®
system sales.
Revenues in the autoimmune and infectious disease line increased by approximately $1,046,000. This increase is the direct result of an initiative taken to place automated lab equipment in large labs that would drive
the sales of the consumables. The Company also relaunched its ENA autoimmune product, which is primarily used in Brazil.
10
Revenues decreased by approximately by
approximately $45,000 in the Endocheck product line. The Company expects to see a continuous decline in this area as we continue to try to convert existing Endocheck customers over to the new Analyst
®
III systems.
The Company believes it will be able
to continue increasing its revenues by increasing shipments of the new Analyst
®
III instrument and other related lab system components and related consumables, by re-launching its
Autoimmune EIA kits, and by increasing the sale of its IFA products due to the decision to place automated IFA equipment in large labs. The Company is focused on increasing the product offering and increasing its sales force in order to attract more
customers, as well as to increase business with current customers, however, Hemagen can give no assurance that it will be able to increase revenues in the future.
Cost of product sales from continuing operations increased approximately $997,000 (38%) to approximately $3,603,000 in fiscal 2008 from approximately $2,606,000 in fiscal 2007 due to an overall increase in sales
volume. Gross margins from continuing operations for fiscal year 2008 were 43% as compared to 42% in fiscal year 2007. The gross margins from continuing operations increased 1% in fiscal 2008 primarily as a result of reduced manufacturing labor
related expenses.
Selling, general and administrative expenses from continuing
operations increased by approximately $495,000 during fiscal 2008 to approximately $2,507,000 from approximately $2,012,000 in fiscal 2007. Expenses contributing to this overall increase included increased expense for trade show activity during 2008
of approximately $158,000, increased sales personnel expense in the Analyst
®
division of approximately $86,000, increased depreciation expense of approximately $72,000 for automated lab
equipment purchased during the year for use in Brazil, increased facility expenses of approximately $32,000, and increased bad debt expense of approximately $70,000, combined with an overall increase in costs of approximately $106,000 or 19% of
Brazil SG&A due to the currency fluctuations of the Brazilian Real. The average monthly exchange rate during fiscal 2007 was 2.04, compared to the average monthly exchange rate of 1.71 during fiscal 2008.
Research and development expenses from continuing operations for fiscal 2008 increased
approximately $119,000 (425%) to approximately $147,000 from $28,000, in the previous year. Most of this increase relates to development work related to the Analyst
®
business.
For the fiscal year 2008, Hemagen had operating income from continuing operations of approximately $130,000 as compared to a $159,000 loss
for the previous fiscal year. This increase of $288,000 in operating income is the result of increased revenues combined with a slightly higher margin in 2008.
Interest expense (net) for fiscal 2008 decreased by approximately $22,000 to $376,000 in 2008 from $401,000 in the prior year. This reduction in net interest expense was attributable to an increase in interest income
generated from the note receivable of approximately $60,000 offset by an increase in interest expense related to notes for the purchase of the automated lab equipment in Brazil as well as increased interest due on the outstanding amounts of the line
of credit.
During fiscal 2007, the company made the decision that a previous accrual that had been carried on the books during prior years
was no longer deemed payable and therefore it was reversed. This transaction generated approximately $301,000 of other income for fiscal 2007.
In the current fiscal year, the Company had approximately $129,000 of income tax expense as compared to $48,000 in fiscal year 2007. All of the income tax expense is related to the Company’s Brazilian subsidiary and represents the net
tax expense after adjusting the benefit of loss carry-forwards utilized according to Brazilian tax law.
The income (loss) reported from
discontinued operations of the Raichem division was approximately $801,000 compared to a $538,000 loss in the prior year. The current year income included approximately $1,095,000 gain on the sale of the Raichem division.
Net income for fiscal 2008 increased by approximately $1,277,000 to $427,000 of net income compared to a net loss of approximately $850,000 in the
previous year. The majority of the increase is attributable to the (net) gain on of approximately $800,000 from the sale of its subsidiary Reagent Applications, Inc. and the increase in gross margin during fiscal 2008 of approximately $764,000
offset by increased expenses relating to trade show activity, deprecation, payroll and the fluctuations of the Brazilian Real.
11
Liquidity and Capital Resources
At September 30, 2008, Hemagen had $98,799 of unrestricted cash, working deficit of $2,225,607 and a current ratio of .6 to 1.0. Included in the calculation of working capital and the
current ratio is approximately $3,979,000 of subordinated debt which is due on September 30, 2009. During the upcoming fiscal year, the Company expects to restructure the debt by, amount other things, extending the maturity date of the notes
representing such debt, but no assurances can be made in this regard. Excluding the subordinated debt in the calculation of working capital, which assumes that it is restructured successfully, results in working capital of $1,753,393 and a current
ratio of 2.1 to 1.0. Notwithstanding, Hemagen can give no assurances that it will have sufficient cash flow to finance its operations.
Hemagen has a revolving line of credit with a bank for the purpose of financing working capital needs as required. The line of credit facility currently provides for borrowings up to $500,000, at an annual interest rate of the prime rate
plus 3/4%. As of September 30, 2008 and December 16, 2008, the Company had $500,000 as outstanding borrowings on the line of credit.
During fiscal 2008, Hemagen had capital expenditures of approximately $607,000, primarily for the purchase of automated lab equipment for use in Brazil. Hemagen Brazil financed approximately $238,000 of these expenditures during 2008 with
bank notes secured by Brazilian receivables.
Cash provided by operating activities was approximately $265,000, cash used by investing
activities was approximately $185,000 and cash provided from financing activities generated approximately $39,000 of cash. The effect of exchange rates on cash in fiscal year 2008 resulted in a negative adjustment of approximately $27,000.
Hemagen believes that cash flow from operations and cash on hand at September 30, 2008 will be sufficient to finance its operations
for fiscal 2009. The line of credit matures on March 31, 2009, and the Company expects to renew the line at that time. However, Hemagen can give no assurances that it will have sufficient cash to repay the line of credit if it is not renewed or
finance its operations.
On September 30, 2009, Hemagen’s Senior Subordinated Secured Convertible Notes outstanding in the amount
of $4,049,850 become due and payable. Hemagen does not have sufficient cash to repay these Notes and therefore expects to restructure the debt by, amount other things, extending the maturity date of the notes. However, Hemagen can give no assurances
that it will be able to refinance or repay these notes.
Fiscal 2008 compared to Fiscal 2007
Hemagen provided $265,000 of cash in its operating activities during fiscal 2008 compared to using $482,000 in cash in its operating activities in fiscal
2007. The cash provided from the change in operating assets and liabilities was approximately $460,000 in fiscal 2008 compared to $260,000 during fiscal 2007. A large portion of the operating cash provided during the year was generated from the sale
of inventory from the Company’s subsidiary in San Diego, which had been sold. (The purchaser of Reagents Applications, Inc. signed an inventory agreement agreeing to continue to buy inventory for a period of eighteen months subsequent to the
sale.)
Cash used by investing activities totaled approximately $185,000 in fiscal 2008, as compared to approximately $51,000 in fiscal
2007. The increase in cash utilized in fiscal 2008 was mainly attributable to the purchase of property and equipment. The majority of this purchase was for automated lab equipment for the Brazil operations. The Company also received principal
payments in the amount of $175,000 against its note receivable during fiscal 2008.
Cash provided by financing activities totaled
approximately $39,000 in fiscal 2008 as compared to $340,000 provided in fiscal 2007. The cash generated during the current year represents an additional $160,000 of borrowings on the Company’s line of credit facility during 2008, offset by
note payments to the Brazilian Itau bank. These notes were established to finance the purchase of lab equipment used in Brazil.
12
New Accounting Pronouncements
Financial Accounting Standards No. 157 (“FAS 157”)
. In September 2006, the Financial Accounting Standards Board (“FASB”) issued FAS 157, “Fair Value
Measurements”. FAS 157 defines fair values , established a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. FAS 157 is effective for financial
statements issued for fiscal years beginning after November 15, 2007. The company does not expect the adoption of FAS 157 to significantly affect its consolidated financial condition of results of operations.
Financial Accounting Standards No 159 (“FAS 159
”). In February 2007, the FASB issued FAS 159
, “
The Fair Value Option for
Financial Assets and Financial Liabilities – Including the amendment of FASB Statement 115
”
, which provides companies with an option to measure eligible financial assets and liabilities in their entirety at fair value. The fair
value option may be applied instrument by instrument, and may be applied only to entire instruments. If a company elects the fair value option for an eligible item, changes in the items fair value must be report as unrealized gains and losses in
earnings at each subsequent reporting date. FAS 159 is effective for fiscal years beginning after November 15, 2007. The Company does not expect the adoption of FAS 159 to significantly affect its consolidated financial condition or results of
operations.
Staff Accounting Bulletin No. 108 (“SAB 108”)
. In September 2006, the Securities and Exchange Commission
(“SEC”) released SAB 108 to address diversity in practice regarding consideration of the effects of prior year’s errors when quantifying misstatements in current year financial statements. The SEC staff concluded that registrants
should quantify financial statement errors using both a balance sheet approach and an income statement approach and evaluate whether either approach results in quantifying a misstatement that, when all relevant quantitative and qualitative factors
are considered, is material. SAB 108 states that if a correcting an error in the current year materially affects the current year’s income statement, the prior period financial statements must be restated. SAB 108 is effective for fiscal years
ending after November 15, 2006. The Company adopted SAB 108 in fiscal 2007. The adoption of SAB 108 did not materially affect the Company’s consolidated financial statements.
SFAS No. 141(R), “Business Combinations–a Replacement of FASB Statement No. 141” (SFAS No. 141 (R))
In December 2007, the FASB issued SFAS 141 (R),
“Business Combinations”. The standard changes the accounting for business combinations including the measurement of acquirer shares issued in consideration for a business combination, the recognition of contingent consideration, the
accounting for preacquisition gain and loss contingencies, the recognition of capitalized in-process research and development, the accounting for acquisition-related restructuring of cost accruals, the treatment of acquisition related transaction
costs and the recognition of changes in the acquirer’s income tax valuation allowance. SFAS 141 (R) is effective for fiscal years beginning after December 15, 2008, with early adoption prohibited. The Company does not expect the
adoption of SFAS 141 to significantly affect its consolidated financial statements.
SFAS No. 160, “Noncontrolling Interests
in Consolidated Financial Statements–an Amendment of ARB No. 51” (SFAS No. 160)
In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements”. SFAS No. 160
will change the accounting for minority interests, which will be recharacterized as noncontrolling interests and classified by the parent company as a component of equity. This statement is effective for fiscal years beginning on or after
December 15, 2008, with early adoption prohibited. Upon adoption, SFAS No. 160 requires retroactive adoption of the presentation and disclosure requirements for existing minority interests and prospective adoption for all other
requirements. The Company does not expect the adoption of SFAS 160 to significantly affect its consolidated financial statements.
In April
2008, the FASB issued FASB Staff Position (FSP), FAS 142-3, “
Determination of the Useful Life of Intangible Assets
”, which amends the factors that should be considered in developing renewal or extension assumptions used to determine
the useful life of a recognized intangible asset under SFAS No. 142, “
Goodwill and Other Intangible Assets
”. This FSP shall be effective for financial statements issued for fiscal years beginning after December 15, 2008,
and interim periods within those fiscal years. Early adoption is prohibited. The Company will ascertain its impact, if any, during the three-month period ending March 31, 2009.
SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities–an Amendment of FASB Statement No. 133” (SFAS No. 161)
During March 2008, the
FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities
”
(“SFAS 161”). SFAS 161 requires entities to provide enhanced disclosures about how and why derivative
instruments are used, how derivative instruments and related hedged items are accounted for under SFAS No. 133, “Accounting for
13
Derivative Instruments and Hedging Activities” and its related interpretations, and how derivative instruments and related hedged items affect financial
position, financial performance, and cash flows. The Company is currently evaluating the impact, if any, of adopting SFAS 161.
SFAS
No. 162, “The Hierarchy of Generally Accepted Accounting Principles” (SFAS No. 162)
In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles
”
(“SFAS
162”). SFAS 162 identifies the sources of accounting principles and the framework for selecting principles to be used in the preparation of financial statements of nongovernmental entities that are presented in conformity with generally
accepted accounting principles in the United States. This statement shall be effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board’s amendments to AU section 411, “The Meaning of Present
Fairly in Conformity with Generally Accepted Accounting Principles
”
. The Company is currently evaluating the impact of adopting SFAS 162 on its consolidated financial statements.
Critical Accounting Policies
The
preparation of consolidated financial statements requires us to make estimates and judgments with respect to the selection and application of accounting policies that affect the reporting of amounts of assets, liabilities, revenues and expenses, and
the disclosures of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies and estimates have the greatest impact on the preparation of our consolidated financial statements:
Revenue Recognition
The Company manufactures and markets a broad offering of
in vitro
diagnostic products and services which currently include: (1) reagents and consumables for general chemistry analyzers; (2) medical diagnostic test kits; (3) medical diagnostic instruments; and (4) maintenance
services. Reagents and consumables, in addition to medical test kits, represent the largest portion of our sales. Revenues from reagents and consumables and test kits are recognized when the product is shipped, all contractual obligations have been
satisfied and it is reasonably assured that the resulting receivable is collectible.
Instruments are usually sold either directly to the
customer or to a third party financing entity that in turn leases it to the end customer. Instrument revenue is recognized upon shipment, when all contractual obligations have been satisfied and it is reasonably assured that the resulting receivable
is collectible.
Revenues under product service contracts, which are generally for one year or less, are recognized ratably over the term
of the contract, based on the relative fair value of the contracts.
Accounts Receivable
The majority of the Company’s accounts receivable are due from distributors (domestic and international), hospitals, universities, and physician and
veterinary offices and other entities in the medical field. Credit is extended based on evaluation of a customers’ financial condition and, generally, collateral is not required. Accounts receivable are most often due within 30 days and are
stated at amounts due from customers net of an allowance for doubtful accounts. Any accounts outstanding longer than the contractual payment terms are considered past due. We maintain allowances for doubtful accounts based on a number of factors,
including the length of time the accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a
whole. The Company writes-off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. Actual amounts collectible could vary from our estimates
and affect our operating results.
Inventories
Inventories are stated at the lower of cost or market. Market for raw materials is based on replacement costs and, for other inventory classifications, on net realizable value. We regularly review inventory quantities
on hand and record a provision for deterioration, excess and obsolete inventory based primarily on our estimated forecast of product demand and production requirements for the next
14
12 to 18 months, depending on the product. Several factors may influence the realizability of our inventories, including technological change and new product
development. These factors could result in an increase in the amount of obsolete inventory on hand. Additionally, our estimates of future product demand may prove to be inaccurate, in which case we may have understated or overstated the provision
required for excess and obsolete inventory. In the future, if we determine that our inventory was overvalued, we will be required to recognize such costs in cost of goods sold at the time of such determination. Although we make every effort to
ensure the accuracy of our forecasts of future product demand, any significant unanticipated changes in demand or technological developments could have a significant impact on the value of our inventory and our reported operating results.
|
Item 7.
|
Financial Statements.
|
See
Item 13 below and the Index therein for a listing of the financial statements and supplementary data filed as part of this report.
|
Item 8.
|
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
|
On September 13, 2007, the Audit Committee of the Board of Directors dismissed Grant Thornton LLP as the Company’s independent registered public
accounting firm. On that same date, the Audit Committee engaged Stegman and Company (the “New Auditor”) as the Company’s independent registered public accounting firm effective September 13, 2007. Grant Thornton’s report on
the Company’s financial statements for each of the last two fiscal years did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles. During the
Company’s two most recent fiscal years and the subsequent interim period preceding the dismissal of Grant Thornton, there were no disagreements on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure which, if not resolved to the satisfaction of Grant Thornton, would have caused it to make a reference to the subject matter in connection with its report. During the Company’s two most recent fiscal years and the subsequent
interim period preceding Grant Thornton’s dismissal, there have been no reportable events (as defined in Regulation S-B Item 304(a)(1)). During the two most recent fiscal years and the interim period prior to engaging the New Auditor,
neither the Company nor anyone on its behalf consulted the New Auditor regarding (i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered
on the Company’s financial statements, and no written report or oral advice was provided to the Company that the New Auditor concluded was an important factor considered by the Company in reaching a decision as an accounting, auditing or
financial reporting issue; or (ii) any matter that was the subject of a disagreement or a reportable event (as defined in Regulation S-B Item 304(a)(1)). The Company requested that Grant Thornton furnish it with a letter addressed to the
Securities and Exchange Commission stating whether it agrees with the above statements. A copy of such letter, dated September 18, 2007, was filed as Exhibit 16 to the Form 8-K filed on September 18, 2007.
Item 8A(T). Controls and Procedures.
Management’s Evaluation of Disclosure Controls and Procedures
The Company’s Chief
Executive Officer, William P. Hales, and the Company’s Principal Financial Officer, Catherine M. Davidson, have evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of
September 30, 2008. Based upon this evaluation, these officers believe that the Company’s disclosure controls and procedures were effective as of September 30, 2008.
Management is aware that there is a lack of segregation of duties due to the small number of employees within the financial and administrative functions of the Company. As a result of the
limitations of the resources and segregation of duties, Stegman and Company, the Company’s current auditor concurs with management’s assessment that these limitations represent a material weakness in internal control over financial
reporting. Management will continue to evaluate this segregation of duties issue. The Company has worked over the past year and has documented these internal controls. As a result of management’s evaluation, the Chief Executive Officer and
Principal Financial Officer concluded that, as of September 30, 2008, the Company’s disclosure controls and procedures were ineffective. This material weakness has not been remediated.
The internal control report is included in this Annual Report on Form 10-KSB filed herewith, under the caption “Management’s Report on Internal
Control Over Financial Reporting.”
15
Changes in Internal Control Over Financial Reporting
There has been no change in the Company’s internal control over financial reporting identified in connection with the evaluation of internal controls
that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to affect, Hemagen’s internal control over financial reporting.
|
Item 8B.
|
Other Information.
|
Not applicable.
PART III
Executive Officers and Directors
|
Item 9.
|
Directors, Executive Officers, Promoters, Control Persons and Corporate Governance; Compliance With Section 16 (a) of the Exchange Act.
|
The following table presents information regarding the Directors of the registrant.
|
|
|
|
|
Dr. Alan S. Cohen
Director Since 1993
Term Expires 2009
Age: 82
|
|
Dr. Cohen has served as a Director of Hemagen since its inception. Dr. Cohen has been a Professor of Medicine at Boston University School of Medicine since 1968 and a
Professor of Pharmacology since 1974. He is currently Distinguished Professor of Medicine (E). Dr. Cohen is Editor-in-Chief of AMYLOID. The Journal of Protein Folding Disorders. Dr. Cohen served as the Director of the Arthritis Center of Boston
University from 1976 to 1994. From 1973 to 1992, Dr. Cohen served as Chief of Medicine of Boston City Hospital. Dr. Cohen is a past president of the American College of Rheumatology. Dr. Cohen received his Bachelor of Arts degree from Harvard
College and his M.D. degree from the Boston University School of Medicine.
|
|
|
|
|
Richard Edwards
Director Since 2003
Term Expires 2009
Age: 49
|
|
Mr. Edwards has served as the Chief Financial Officer of TrustAtlantic Financial Corporation since 2006. Prior to joining TrustAtlantic, he served as Chief Financial Officer
of Square 1 Financial Inc., a privately held bank holding company, from August 2005 to September 2006. Prior to joining Square 1 Financial, he served as Chief Financial Officer of Capital Bank Corporation, a publicly traded bank holding company,
from April 2004 to August 2005. He served as Senior Vice President and the Chief Accounting Officer of National Commerce Financial Corporation, a NYSE traded bank holding company, from July 2002 to April 2004. From January 2001 to July 2002, Mr.
Edwards was the Chief Financial Officer of New South Bancshares, Inc. He spent eight years in various senior financial roles with Bank of America prior to January 2001 and eight years in public accounting with Ernst & Young prior to that. Mr.
Edwards earned a B.S. degree in accounting from the University of Illinois and is a member of the AICPA. Mr. Edwards notified management of his intention to not stand for reelection at the 2009 Annual Meeting.
|
|
|
|
|
William P. Hales
Director since 1999
Term Expires 2010
Age: 46
|
|
William P. Hales has been a Director of Hemagen and its President since October 1, 1999 and its Chairman of the Board of Directors since February 2004. Mr. Hales has served
as Hemagen’s CEO since 2002. From 1997 to January 2001. Mr. Hales was an Investment Banker and Advisor with Jesup & Lamont Securities Corporation, an investment banking and brokerage firm. Prior to that, Mr. Hales spent six years in public
accounting with Ernst & Young and Coopers & Lybrand advising clients on both audit and management consulting.
|
|
|
|
|
Edward T. Lutz
Director since 2004
Term Expires 2010
Age: 62
|
|
Mr. Lutz has been the President and CEO of Lutz Advisors, Inc. since 2001. Prior to that Mr. Lutz served Tucker Anthony Sutro Capital Markets within the Investment Banking
Group focusing on the bank and thrift industry. He has over thirty-five years experience in bank regulation, mergers and acquisitions of troubled financial institutions, strategic planning and structuring financial transactions. Over the last 13
years he has specialized in investment banking and consulting to bank and thrift institutions. Mr. Lutz was a member of the board of directors of Union State Bank (NYSE) and U.S.B Holding Bank. Mr. Lutz earned his B.A. in Economics from Hofsta
University and his M.B.A in Finance from American University.
|
16
The executive officers as of the date of this report:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
|
William P. Hales
|
|
46
|
|
Chairman of the Board, President and Chief Executive Officer
|
|
Catherine M. Davidson
|
|
43
|
|
Controller, Principal Financial and Accounting Officer
|
Our Directors will serve until the next annual meeting of stockholders. Our executive officers are
appointed by our Board of Directors and serve at the discretion of the Board of Directors.
Audit Committee
The Audit Committee is comprised of Richard W. Edwards (Chairman), Edward T. Lutz, and William P. Hales. The Board of Directors has determined that each
of Mr. Edwards and Mr. Lutz meet the standards for independence provided under the Sarbanes-Oxley Act of 2002. All members meet standards of financial literacy. The Board has also determined that each of Mr. Edwards and Mr. Lutz
qualify as an audit committee financial expert as defined in regulations adopted by the Securities and Exchange Commission.
Compliance
with Section 16(a) of the Exchange Act
Section 16 of the Securities Exchange Act of 1934 requires Hemagen’s executive
officers, Directors and persons who own more than 10% of a registered class of Hemagen’s equity securities to file reports of ownership and changes in ownership with the Securities and Exchange Commission. Based on a review of reports received
by it, and upon written representations from the reporting persons, Hemagen believes that during the last fiscal year, all of its executive officers, Directors and 10% shareholders complied with Section 16 reporting with the exception that
Mrs. Davidson filed one late ownership report with respect to one transaction.
Code of Ethics
The Registrant has adopted a Code of Ethics that applies to all of our Directors, officers and employees. The Code of Ethics was filed with the
Registrant’s Form 10-KSB for the fiscal year ended September 30, 2003, a copy of which is available to any person without charge upon request to the Secretary.
|
Item 10.
|
Summary Compensation Table.
|
SUMMARY COMPENSATION TABLE
The following sets forth compensation paid, earned or awarded to the CEO and the other most
highly paid executive officers during the last two fiscal years ended September 30:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name and
Principal
Position
(a)
|
|
Year
(b)
|
|
Salary
($)
(c)
|
|
|
Bonus
($)
(d)
|
|
Stock
Awards
($)
(e)
|
|
Option
Awards
($)
(f)
|
|
Non-Equity
Incentive Plan
Compensation
($)
(g)
|
|
Nonqualified
Deferred
Compensation
Earnings
($)
(h)
|
|
All Other
Compensation
($)
(i)
|
|
|
Total
($)
(j)
|
|
William P. Hales
|
|
2008
|
|
172,500
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
41,124
|
(1)
|
|
213,624
|
|
|
|
2007
|
|
172,500
|
|
|
—
|
|
—
|
|
—
|
|
—
|
|
—
|
|
38,743
|
(2)
|
|
211,243
|
|
Catherine M. Davidson
|
|
2008
|
|
115,000
|
|
|
5,000
|
|
|
|
1,187
|
|
|
|
|
|
2,000
|
(4)
|
|
123,187
|
|
|
|
2007
|
|
50,570
|
(3)
|
|
—
|
|
—
|
|
4,440
|
|
—
|
|
—
|
|
1,161
|
(5)
|
|
56,171
|
|
(1)
|
Represents $26,760 in provision for the use of a company apartment $8,364 for a leased car and $6,000 estimated for the Company’s contributions in the
Employee Stock Ownership Plan for the plan year ending September 2008.
|
|
(2)
|
Represents $26,760 in provision for the use of a company apartment, and $8,364 for a leased car and $3,619 for the Company’s contributions in the Employee
Stock Ownership Plan for the plan year ending September 2007.
|
|
(3)
|
Represents salary paid for fiscal 2007. Mrs. Davidson started with the company in April 2007.
|
|
(4)
|
Represents Company’s estimated contributions in the Employee Stock Ownership plan for plan year ending September 2008.
|
|
(5)
|
Represents Company’s contributions in the Employee Stock Ownership plan for year ending September 2007.
|
17
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
Name
(a)
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Exercisable
(b)
|
|
Number of
Securities
Underlying
Unexercised
Options (#)
Unexercisable
(c)
|
|
Equity
Incentive
Plan
Awards
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)
(d)
|
|
Option
Exercise
Price
($)
(e)
|
|
Option
Expiration
Date
(f)
|
|
Number
of
Shares
or Units
of Stock
That
Have
Not
Vested
(#)
(g)
|
|
Market
Value
of
Shares
or Units
of Stock
That
Have
Not
Vested
($)
(h)
|
|
Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have
Not
Vested
(#)
(i)
|
|
Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares,
Units
or
Other
Rights
That
Have Not
Vested
($)
(j)
|
|
William P. Hales
|
|
1,630,148
250,000
|
|
—
—
|
|
—
—
|
|
1.36
.20
|
|
09/30/2009
10/25/2015
|
|
—
—
|
|
—
—
|
|
—
—
|
|
—
—
|
|
Catherine M. Davidson
|
|
7,000
—
|
|
28,000
10,000
|
|
—
—
|
|
.22
.19
|
|
04/23/2012
01/10/2013
|
|
—
—
|
|
—
—
|
|
—
—
|
|
—
—
|
Director Compensation
Non-employee Directors are paid $3,500 per quarter. Such compensation is paid as follows; $2,000 of the compensation per quarter is invested in Hemagen’s common stock in open market
purchases under a Rule 10b5-1 Stock Purchase Plan. The remaining $1,500 per quarter is paid in cash. Non-employee Directors of the Company are granted an option to purchase 10,000 shares of the Company’s common stock at the election
of their three-year term. In addition, Non-employee Directors that serve on a committee or committees of the Board of Directors are granted an option to purchase 5,000 shares of the Company’s common stock at the annual appointment of their
position. Commencing October 1, 2008 the Director’s quarterly compensation plan was changed. The Director’s will now receive a cash payment of $2,500 and 5,000 shares of Hemagen stock each quarter.
Prior to fiscal year 2006, the options awarded to Directors were issued pursuant to the 2000 Directors’ Stock Option Plan. Options previously
awarded under the 2000 Directors’ Stock Option Plan had an exercise price equal to the fair market value of the underlying shares on the date of the grant, and will expire ten years from the date of the grant. In fiscal year 2007, the
stockholders approved the 2007 Stock Incentive Plan, which authorizes the issuance of option awards to Directors; however, no options were awarded to Directors pursuant to this plan during fiscal year 2007. Consequently, options that would have
been awarded in fiscal 2005 and fiscal 2006 to each Director but for the expiration of the Directors’ Stock Option Plan and options that are authorized to be awarded to each Director in 2007 pursuant to the 2007 Stock Incentive Plan were
accrued and awarded to the Directors in fiscal year 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
(a)
|
|
Fees
Earned
or Paid
in
Cash
($)
(b)
|
|
Stock
Awards
($)
(c)
|
|
Option
Awards
($)
(d)
|
|
Non-Equity
Incentive Plan
Compensation
($)
(e)
|
|
Nonqualified
Deferred
Compensation
Earnings
($)
(f)
|
|
All Other
Compensation
($)
(g)
|
|
Total
($)
(h)
|
|
Alan S. Cohen
|
|
6,000
|
|
8,000
|
|
5,117
|
|
—
|
|
—
|
|
—
|
|
19,117
|
|
Richard W. Edwards
|
|
6,000
|
|
8,000
|
|
5,117
|
|
—
|
|
—
|
|
—
|
|
19,117
|
|
Edward T. Lutz
|
|
6,000
|
|
8,000
|
|
5,137
|
|
—
|
|
—
|
|
|
|
19,137
|
18
|
Item 11.
|
Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters.
|
Beneficial Ownership of Common Stock
The following table reports information regarding the beneficial ownership of our common stock as of November 21, 2008, by each person or entity known by us to be the beneficial owner of more than 5% of the outstanding shares of common
stock, each of our Directors and named executive officers, and all of our Directors and executive officers as a group.
|
|
|
|
|
|
|
|
|
|
|
Title of Class
|
|
Name and Address of Beneficial Owner
|
|
Amount and
Nature Of
Beneficial
Owner
|
|
|
Percent of
Class
|
|
|
Common Stock
|
|
William P. Hales
President & CEO, Director
9033 Red Branch Rd.
Columbia, MD 21045
|
|
3,740,692
|
(1)
|
|
20.7
|
%
|
|
Common Stock
|
|
Jonathan E. Rothschild
1061-B Shary Circle
Concord, CA 94518
|
|
1,133,021
|
(2)
|
|
7.4
|
%
|
|
Common Stock
|
|
Dr. Alan Cohen
Director
54 Winston Rd.
Newtown, MA
02459
|
|
348,074
|
(3)
|
|
1.9
|
%
|
|
Common Stock
|
|
Richard W. Edwards
Director
9316 Teton Pines Way
Raleigh, NC 27617
|
|
168,712
|
(4)
|
|
0.9
|
%
|
|
Common Stock
|
|
Edward T. Lutz
Director
6 West Sanders St.
Greenlawn,
NY 11740
|
|
168,434
|
(5)
|
|
0.9
|
%
|
|
Common Stock
|
|
Catherine M. Davidson
Controller, Principal Financial and Accounting Officer
9033 Red Branch Road
Columbia, MD 21045
|
|
46,698
|
(6)
|
|
0.3
|
%
|
|
Common Stock
|
|
All Directors and Executive Officers as a Group
|
|
4,472,610
|
|
|
24.8
|
%
|
|
(1)
|
Includes 1,880,148 shares issuable upon the exercise of options within 60 days, senior subordinated secured convertible notes convertible into 691,600 shares of
common stock within 60 days and 35,494 shares in the employee ESOP plan as of the plan year ending September 30, 2007.
|
|
(2)
|
Based on Mr. Rothchild’s most recent ownership report filed with the SEC.
|
|
(3)
|
Includes 75,000 shares issuable upon the exercise of options within 60 days and 1,528 undistributed shares in Directors’ 10b5-1 Plan.
|
|
(4)
|
Amounts include 4,500 shares held jointly with spouse, 3,100 owned by a family member over which Mr. Edwards has joint investment authority, 99,584 shares
held directly, and 1,528 undistributed shares in Directors’ 10b5-1 Plan. Includes options to purchase 60,000 shares exercisable within 60 days.
|
|
(5)
|
Includes 55,000 shares issuable upon the exercise of options within 60 days and 1,528 undistributed shares in Directors’ 10b5-1 Plan
|
|
(6)
|
Share ownership includes an unvested option to purchase 38,000 shares, 7,000 shares issuable upon the exercise of options within 60 days and 1,698 shares in the
employee ESOP plan as of the plan year ending September 30, 2007.
|
19
Securities Authorized for Issuance under Equity Compensation Plans
The following table sets forth our Securities authorized for issuance under our currently effective Equity Compensation Plans.
|
|
|
|
|
|
|
|
|
|
|
|
Plan category
|
|
Number of securities to be
issued upon exercise of
outstanding options,
warrants and
rights
|
|
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
|
|
Number of securities
remaining available for future
issuance under equity
compensation
plans
(excluding securities
reflected in column (a))
|
|
|
Equity compensation plans approved by security holders
|
|
2,464,014
|
(1)
|
|
$
|
1.05
|
|
1,858,000
|
(2)
|
|
Equity compensation plans not approved by security holders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
2,464,014
|
(1)
|
|
$
|
1.05
|
|
1,858,000
|
(2)
|
|
1.
|
Amount includes 1,732,014 options for the purchase of common stock approved by the shareholders in conjunction with the consent solicitation which resulted in
the replacement of certain former members of the Company’s senior management and Board of Directors on September 30, 1999, 522,000 options for the purchase of common stock pursuant to the Company’s 2001 Stock Option Plan approved by
the shareholders on February 27, 2001, 90,000 options for the purchase of common stock pursuant to the Company’s 2000 Directors’ Stock Option Plan approved by the shareholders on April 25, 2000, and 120,000 option for purchases
of common stock pursuant to the Company’s 2007 Stock Option Plan approved by the shareholders on April 24, 2007 that have been issued as of September 30, 2008.
|
|
2.
|
Amount represents options for the purchase of common stock approved by the shareholders pursuant to the Company’s 2001 Stock Option Plan and the 2007 Stock
Option plan that have not been issued as of as of September 30, 2008.
|
|
Item 12.
|
Certain Relationships and Related Transactions, and Directors Independence.
|
Director Independence
In accordance with NASDAQ rules, the Board of Directors
affirmatively determines the independence of each director and nominee for election as a director. Edward T. Lutz, Dr. Alan S. Cohen and Richard W. Edwards, who comprise a majority of the Board of Directors, are “independent”
directors as independence is defined by the applicable rules of NASDAQ and the Securities and Exchange Commission.
(a)(1) and
(2)
Financial Statements and Schedules
20
(a)(3) Exhibit List.
|
|
|
|
|
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
|
3.1
|
|
Certificate of Incorporation (Incorporated by reference to Registration Statement No. 33-52686-B)
|
|
|
|
|
3.2
|
|
Bylaws (Incorporated by reference to Registration Statement No. 33-52686-B)
|
|
|
|
|
4.1
|
|
Specimen Stock Certificate (Incorporated by reference to Registration Statement on Form 8-A filed with the Commission on February 10, 1999)
|
|
|
|
|
4.2
|
|
Rights Agreement dated January 27, 1999 (Incorporated by reference to Registration Statement on Form 8-A filed with the Commission on February 10, 1999)
|
|
|
|
|
4.3
|
|
First Amendment to the Rights Agreement dated September 30, 1999 (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal year ended September 30,
2000)
|
|
|
|
|
10.17
|
|
Description of the Lease for office space of HDC in Sao Paulo, Brazil (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal year ended September 30, 2005)
|
|
|
|
|
10.25
|
|
Settlement agreement dated September 30, 1999 (Incorporated by reference to Hemagen’s Form 8-K filed with the Commission on October 7, 1999)
|
|
|
|
|
10.29
|
|
Form of 8% Senior Subordinated Secured Convertible Note (Incorporated by reference Hemagen’s Registration Statement No. No. 333-40606 filed on Form S-3 filed with the
Commission on June 30, 2000)
|
|
|
|
|
10.30
|
|
Second Amendment to the Lease between the Company and 9033 Red Branch Road, L.L.C. dated June 9, 2000 (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal
year ended September 30, 2000)
|
|
|
|
|
10.32
|
|
Second Restructuring Agreement between the Company and Dade Behring, Inc. dated November 9, 2000 (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal year
ended September 30, 2001)
|
|
|
|
|
10.33*
|
|
2000 Directors’ Stock Option Plan (Filed herewith)
|
|
|
|
|
10.35*
|
|
2001 Stock Option Plan (Incorporated by reference to Hemagen’s Definitive Proxy Statement filed with the Commission on January 29, 2001)
|
|
|
|
|
10.40
|
|
Line of Credit Financing Agreement between Hemagen Diagnostics, Inc. and Reagents Applications, Inc. and Bay National Bank dated September 26, 2002 (Incorporated by reference
to Hemagen’s Form 10-KSB for the fiscal year ended September 30, 2002)
|
|
|
|
|
10.42*
|
|
Directors Rule 10b5-1 Stock Purchase Plan (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal year ended September 30, 2003)
|
|
|
|
|
10.44*
|
|
Hemagen Employee Stock Ownership Plan (Incorporated by reference to Hemagen’s Form 10-KSB for the year ended September 30, 2004)
|
|
|
|
|
10.45*
|
|
Trust Agreement for the Hemagen Employee Stock Ownership Plan (Incorporated by reference to Hemagen’s Form 10-KSB for the year ended September 30,
2004)
|
|
|
|
|
10.50
|
|
Quota Purchase and Sale Agreement and Non-Competition Agreement (Incorporated by reference to Hemagen’s Form 10-KSB for the year ended September 30,
2004)
|
|
|
|
|
10.52
|
|
Form of 8% Senior Subordinated Secured Convertible Note dated September 30, 2004 (Incorporated by reference to Hemagen’s Form 10-KSB for the year ended September 30,
2005)
|
|
|
|
|
10.60*
|
|
2007 Incentive Plan (Incorporated by reference to Hemagen’s Definitive Proxy Statement filed with the Commission on March 21, 2007)
|
21
|
|
|
|
|
|
|
|
10.65
|
|
Third Amendment to the Lease between the Company and 9033 Red Branch Road, L.L.C. dated June 9, 2000 (Incorporated by reference to Hemagen’s Form 8-K filed with the
Commission on September 12, 2007)
|
|
|
|
|
10.70
|
|
Asset Purchase Agreement between Reagents Applications, Inc. and Cliniqa Corporation dated October 8, 2007 (Incorporated by reference to Hemagen’s Form 8-K filed with
the Commission on October 12, 2007)
|
|
|
|
|
10.75
|
|
Promissory Note between Hemagen Diagnostics, Inc. and Cliniqa Corporation dated October 8, 2007 (Incorporated by reference to Hemagen’s Form 8-K filed with the
Commission on October 12, 2007)
|
|
|
|
|
10.80
|
|
Inventory Purchase Agreement between Reagents Applications, Inc. and Cliniqa Corporation dated October 8, 2007 (Incorporated by reference to Hemagen’s Form 8-K filed
with the Commission on October 12, 2007)
|
|
|
|
|
14
|
|
Code of Ethics Policy (Incorporated by reference to Hemagen’s Form 10-KSB for the fiscal year ended September 30, 2003)
|
|
|
|
|
16
|
|
Letter from Grant Thornton LLP to the Commission (Incorporated by reference to Hemagen’s Form 8-K filed with the Commission on September 18, 2007)
|
|
|
|
|
23.1
|
|
Consent of Stegman and Company (Filed herewith)
|
|
|
|
|
31.1
|
|
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) (Filed herewith)
|
|
|
|
|
31.2
|
|
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) (Filed herewith)
|
|
|
|
|
32.1
|
|
Section 1350 Certification of Chief Executive Officer (Filed herewith)
|
|
|
|
|
32.2
|
|
Section 1350 Certification of Chief Financial Officer (Filed herewith)
|
|
*
|
Management compensatory contracts.
|
Hemagen will provide shareholders with any exhibit upon the payment of a specified reasonable fee, which fee shall be limited to Meridian’s reasonable expenses in furnishing such exhibit.
22
|
Item 14.
|
Principal Accountant Fees and Services.
|
Hemagen’s independent public accountants are Stegman and Company. Stegman and Company has served in that capacity since fiscal year 2007. Aggregate fees billed to Hemagen in fiscal 2008 by its principal
accountants, Stegman and Company and in fiscal 2007 by its principal accountants first, Grant Thornton LLP and then later, Stegman and Company were:
|
|
|
|
|
|
|
|
|
|
|
|
|
2007
|
|
|
2008
|
|
|
Audit fees and SAS 100 quarterly review related fees
|
|
$
|
143,600
|
|
|
$
|
58,803
|
|
|
Audit- related Fees
|
|
$
|
0
|
|
|
$
|
0
|
|
|
Tax Fees
|
|
$
|
13,075
|
(a)
|
|
$
|
11,000
|
(a)
|
|
All Other Fees
|
|
$
|
0
|
|
|
$
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
111,375
|
|
|
$
|
69,803
|
|
|
|
|
|
|
|
|
|
|
|
|
(a)
|
The Audit Committee believes the provision of these services is compatible with maintaining the principal accountant’s independence.
|
Audit Fee
s. Audit services of Stegman and Company for fiscal 2008 and 2007 consisted of
examination of the consolidated financial statements of the Company, quarterly reviews of the financial statements and services related to the filings made with the Securities and Exchange Commission. During fiscal year 2007, Grant Thornton LLP
performed the quarterly reviews for the first three quarters of the year and provided a consent on the audited financial statements for fiscal 2007.
Tax Fees.
Tax fees included charges primarily related to the preparation of federal and state tax returns.
All Other Fees
. This represents fees charged by Stegman and Company for permissable services other than those described under “Audit Fees” and “Tax Fees” for the 2008 and 2007 fiscal
years, including fees for various planning matters.
All of the services described above were approved by the Audit
Committee. The Audit Committee has not adopted formal pre-approval policies, but has the sole authority to engage the Company’s outside auditing and tax preparation firms and must approve all tax consulting and auditing arrangements with
the independent accounting firm prior to the performance of any services. Approval for such services is evaluated during the Audit Committee meetings and must be documented by signature of an Audit Committee member on the engagement letter of
the independent accounting firm.
23
SIGNATURES
In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
HEMAGEN DIAGNOSTICS, INC.
|
|
|
|
|
|
|
Date: December 19, 2008
|
|
|
|
By:
|
|
/s/ William P. Hales
|
|
|
|
|
|
|
|
William P. Hales, President &
|
|
|
|
|
|
|
|
Chief Executive Officer
|
In accordance with the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
|
|
|
|
|
|
|
Name
|
|
Capacity
|
|
Date
|
|
|
|
|
|
/s/ William P. Hales
William P. Hales
|
|
President and Chief Executive Officer,
Director
|
|
December 19, 2008
|
|
|
|
|
|
/s/ Alan S. Cohen
Alan S. Cohen, M.D.
|
|
Director
|
|
December 19, 2008
|
|
|
|
|
|
/s/ Richard W. Edwards
Richard W. Edwards
|
|
Director
|
|
December 19, 2008
|
|
|
|
|
|
/s/ Edward T. Lutz
Edward T. Lutz
|
|
Director
|
|
December 19, 2008
|
|
|
|
|
|
/s/ Catherine M. Davidson
Catherine M. Davidson
|
|
Principal Financial Officer and
Principal Accounting Officer
|
|
December 19, 2008
|
24
CONTENTS
F-1
Management’s Report on Internal Control over Financial Reporting
The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting
(as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended). The Company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of
records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated
financial statements in accordance with GAAP and that receipts and expenditures of the Company are being made only in accordance with the authorizations of management and the Directors of the Company; and (iii) provide reasonable assurance
regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Consolidated Financial Statements.
Because of its inherent limitations, internal control over financial reporting can only provide reasonable, but not absolute assurance with respect to
financial statement preparation and presentation and may not prevent or detect misstatements. Further, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree or compliance with the policies or procedures may deteriorate.
As required by Section 404 of the
Sarbanes Oxley Act of 2002, management assessed the effectiveness of the Company’s internal control over financial reporting as of September 30, 2008. Management’s assessment is based on the criteria established in the Internal
Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. In assessing the internal controls, management is aware that there is a lack of segregation of duties due to the small number of
employees within the financial and administrative functions of the Company. As a result of the limitations of the resources and segregation of duties, management acknowledges a material weakness in internal control over financial reporting. As a
result, the Company’s Chief Executive Officer and Principal Financial Officer concluded that, as of September 30, 2008, the Company’s disclosure controls and procedures were ineffective. This material weakness has not been remediated.
This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal
control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to
provide only management’s report in this annual report.
|
|
|
/s/ William P. Hales
|
|
William P. Hales
President and Chief Executive Officer
December 19, 2008
|
|
|
|
/s/ Catherine M. Davidson
|
|
Catherine M. Davidson
Principal Financial Officer
December 19, 2008
|
F-2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors of
Hemagen Diagnostics, Inc.
We have audited the consolidated balance sheets of Hemagen Diagnostics, Inc. and subsidiaries as of
September 30, 2008 and 2007 and the related consolidated statements of operations and comprehensive income, changes in stockholders’ deficit, and cash flows for the years then ended. These consolidated financial statements are the
responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement. Hemagen Diagnostics, Inc. is not required to have, nor were we engaged to perform, an audit of the Company’s internal control over financial reporting. Our audits included
consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the Company’s internal
control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements, assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of
Hemagen Diagnostics, Inc. and Subsidiaries as of September 30, 2008 and 2007 and the consolidated results of their operations and comprehensive income and their cash flows for the years then ended, in conformity with accounting principles
generally accepted in the United States of America.
|
|
|
/s/ Stegman and Company
|
|
|
|
Baltimore, Maryland
December 17, 2008
|
F-3
Hemagen Diagnostics, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
As of
September 30, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
2007
|
|
ASSETS
|
|
|
|
|
|
|
|
CURRENT ASSETS:
|
|
|
|
|
|
|
|
Cash
|
|
$
|
98,799
|
|
$
|
6,592
|
|
Accounts Receivable, less allowance for doubtful accounts of $62,485 and $51,316 at September 30, 2008 and
2007,
respectively
|
|
|
866,306
|
|
|
1,000,652
|
|
Inventories, net
|
|
|
2,037,049
|
|
|
2,554,881
|
|
Current Portion of Note Receivable
|
|
|
210,000
|
|
|
—
|
|
Prepaid expenses and other current assets
|
|
|
304,038
|
|
|
250,435
|
|
Assets Held for Sale
|
|
|
—
|
|
|
5,183
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
3,516,192
|
|
|
3,817,743
|
|
|
|
|
|
|
|
|
|
PROPERTY AND EQUIPMENT;
net of accumulated Depreciation and amortization of $5,970,504 and $5,883,861
at
September 30, 2008 and 2007, respectively
|
|
|
697,071
|
|
|
221,990
|
|
OTHER ASSETS:
|
|
|
|
|
|
|
|
Long term portion of Note Receivable
|
|
|
455,000
|
|
|
—
|
|
Other Assets
|
|
|
98,057
|
|
|
95,358
|
|
|
|
|
|
|
|
|
|
Total other assets
|
|
|
553,057
|
|
|
95,358
|
|
|
|
|
|
|
|
|
|
Total Assets
|
|
$
|
4,766,320
|
|
$
|
4,135,091
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements
F-4
Hemagen Diagnostics, Inc. and Subsidiaries
CONSOLIDATED BALANCE SHEETS
As of September 30, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES:
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
1,127,599
|
|
|
$
|
1,332,302
|
|
|
Revolving line of credit
|
|
|
500,000
|
|
|
|
340,000
|
|
|
Deferred revenue
|
|
|
102,680
|
|
|
|
17,691
|
|
|
Note payable – Itau Bank
|
|
|
32,257
|
|
|
|
16,388
|
|
|
Senior subordinated secured convertible notes, net of unamortized discount of $70,587
|
|
|
3,979,263
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
5,741,799
|
|
|
|
1,706,381
|
|
|
|
|
|
|
|
|
|
|
|
|
LONG-TERM LIABILITIES
:
|
|
|
|
|
|
|
|
|
|
Note payable – Itau Bank, net of current portion
|
|
|
119,466
|
|
|
|
18,200
|
|
|
Senior subordinated secured convertible notes, net of unamortized discount of $143,575
|
|
|
—
|
|
|
|
3,906,275
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Long-Term Liabilities
|
|
|
119,466
|
|
|
|
3,924,475
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
5,861,265
|
|
|
|
5,630,856
|
|
|
STOCKHOLDERS’ DEFICIT
|
|
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value - 1,000,000 shares authorized; none issued
|
|
|
—
|
|
|
|
—
|
|
|
Common stock, $0.01 par value - 30,000,000 shares authorized; 15,325,281 shares issued and outstanding at September 30, 2008
and 2007, respectively
|
|
|
153,252
|
|
|
|
153,252
|
|
|
Additional paid-in capital
|
|
|
22,867,507
|
|
|
|
22,842,290
|
|
|
Accumulated deficit
|
|
|
(23,925,977
|
)
|
|
|
(24,353,140
|
)
|
|
Less treasury stock at cost; 100,000 shares at September 30, 2008 and 2007, respectively
|
|
|
(89,637
|
)
|
|
|
(89,637
|
)
|
|
Accumulated other comprehensive loss - currency translation loss
|
|
|
(100,090
|
)
|
|
|
(48,530
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders’ deficit
|
|
|
(1,094,945
|
)
|
|
|
(1,495,765
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders’ deficit
|
|
$
|
4,766,320
|
|
|
$
|
4,135,091
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements
F-5
Hemagen Diagnostics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
For The Years Ended September 30, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Net sales
|
|
$
|
6,374,799
|
|
|
$
|
4,487,236
|
|
|
Cost of sales
|
|
|
3,602,666
|
|
|
|
2,606,122
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
|
|
2,772,133
|
|
|
|
1,881,114
|
|
|
Operating Expenses:
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
2,507,351
|
|
|
|
2,011,733
|
|
|
Research and development
|
|
|
146,748
|
|
|
|
28,221
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
2,654,099
|
|
|
|
2,039,954
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating income (loss) from continuing operations
|
|
|
118,034
|
|
|
|
(158,840
|
)
|
|
Other income (expenses)
|
|
|
|
|
|
|
|
|
|
Interest expense, (net), including $72,988 and $65,710, of debt discount amortization for the periods ending
September 30, 2008 and 2007, respectively
|
|
|
(375,671
|
)
|
|
|
(401,463
|
)
|
|
Reversal of accrued royalty liability
|
|
|
—
|
|
|
|
300,556
|
|
|
Other income (expense)
|
|
|
13,609
|
|
|
|
(4,546
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense
|
|
|
(362,062
|
)
|
|
|
(105,453
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, before income taxes, from continuing operations
|
|
|
(244,028
|
)
|
|
|
(264,293
|
)
|
|
Income tax expense
|
|
|
(129,333
|
)
|
|
|
(47,515
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, from continuing operations
|
|
|
(373,361
|
)
|
|
|
(311,808
|
)
|
|
Income (loss), from Discontinued Operations
|
|
|
800,524
|
|
|
|
(538,123
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income
|
|
$
|
427,163
|
|
|
$
|
(849,931
|
)
|
|
Other comprehensive (loss) income, net of tax:
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment
|
|
$
|
(51,560
|
)
|
|
$
|
55,797
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income (loss)
|
|
|
(51,560
|
)
|
|
|
55,797
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss
|
|
$
|
375,603
|
|
|
$
|
(794,134
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) per share, from continuing operations - Basic
|
|
$
|
(0.02
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) per share, from continuing operations - Diluted
|
|
$
|
(0.02
|
)
|
|
$
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share, from discontinued operations - Basic
|
|
$
|
0.05
|
|
|
$
|
(0.04
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share, from discontinued operations - Diluted
|
|
$
|
0.05
|
|
|
$
|
(0.04
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share - Basic
|
|
$
|
0.03
|
|
|
$
|
(0.06
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share - Diluted
|
|
$
|
0.03
|
|
|
$
|
(0.06
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares used in the calculation of net (loss) income per share - Basic
|
|
|
15,225,289
|
|
|
|
15,225,289
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares used in the calculation of net (loss) income per share - Diluted
|
|
|
15,229,834
|
|
|
|
15,225,289
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements
F-6
Hemagen Diagnostics, Inc. and Subsidiaries
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ DEFICIT
For the Years Ended September 30, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
Additional
Paid-in
Capital
|
|
Accumulated
Deficit
|
|
|
Accumulated
Other
Comprehensive
Loss
|
|
|
Treasury Stock
|
|
|
Total
Stockholders’
Deficit
|
|
|
|
|
Shares
|
|
Par Value
|
|
|
|
|
Shares
|
|
Cost
|
|
|
|
Balance at October 1, 2006
|
|
15,325,281
|
|
$
|
153,252
|
|
$
|
22,836,134
|
|
$
|
(23,503,209
|
)
|
|
$
|
(104,327
|
)
|
|
100,000
|
|
$
|
(89,637
|
)
|
|
$
|
(707,787
|
)
|
|
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(849,931
|
)
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
(849,931
|
)
|
|
Foreign exchange
translation adjustment
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
55,797
|
|
|
—
|
|
|
—
|
|
|
|
55,797
|
|
|
Stock Based Compensation
|
|
—
|
|
|
—
|
|
|
6,156
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
6,156
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2007
|
|
15,325,281
|
|
$
|
153,252
|
|
$
|
22,842,290
|
|
$
|
(24,353,140
|
)
|
|
$
|
(48,530
|
)
|
|
100,000
|
|
$
|
(89,637
|
)
|
|
$
|
(1,495,765
|
)
|
|
Net income
|
|
—
|
|
|
—
|
|
|
—
|
|
|
427,163
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
427,163
|
|
|
Foreign exchange
translation adjustment
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
(51,560
|
)
|
|
—
|
|
|
—
|
|
|
|
(51,560
|
)
|
|
Stock Based Compensation
|
|
—
|
|
|
—
|
|
|
25,217
|
|
|
—
|
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
25,217
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at September 30, 2008
|
|
15,325,281
|
|
$
|
153,252
|
|
$
|
22,867,507
|
|
$
|
(23,925,977
|
)
|
|
$
|
(100,090
|
)
|
|
100,000
|
|
$
|
(89,637
|
)
|
|
$
|
(1,094,945
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements
F-7
Hemagen Diagnostics, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
For The Years Ended September 30, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Cash flows from operating activities
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
427,163
|
|
|
$
|
(849,931
|
)
|
|
Adjustments to reconcile net income (loss) to net cash used in operating activities
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
107,552
|
|
|
|
36,016
|
|
|
Amortization of debt discount
|
|
|
72,988
|
|
|
|
65,710
|
|
|
Stock based compensation
|
|
|
25,217
|
|
|
|
6,156
|
|
|
Bad debt expense
|
|
|
15,847
|
|
|
|
|
|
|
Gain on the sale of assets
|
|
|
(843,632
|
)
|
|
|
—
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
118,499
|
|
|
|
2,721
|
|
|
Inventories
|
|
|
517,832
|
|
|
|
205,900
|
|
|
Prepaid expenses and other assets
|
|
|
(56,302
|
)
|
|
|
(42,812
|
)
|
|
Accounts payable and accrued liabilities
|
|
|
(204,703
|
)
|
|
|
101,412
|
|
|
Deferred revenue
|
|
|
84,989
|
|
|
|
(7,413
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided (used) in operating activities
|
|
|
265,450
|
|
|
|
(482,241
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(368,437
|
)
|
|
|
(51,276
|
)
|
|
Proceeds from the sale of assets
|
|
|
8,815
|
|
|
|
—
|
|
|
Payments received on Note Receivable
|
|
|
175,000
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used by investing activities
|
|
|
(184,622
|
)
|
|
|
(51,276
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|
|
|
Net borrowings from revolving line of credit
|
|
|
160,000
|
|
|
|
340,000
|
|
|
Payments made on Itau Bank Note
|
|
|
(121,162
|
)
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
38,838
|
|
|
|
340,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of exchange rates on cash and cash equivalents
|
|
|
(27,459
|
)
|
|
|
49,446
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
92,207
|
|
|
|
(144,071
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Cash, beginning of year
|
|
|
6,592
|
|
|
|
150,663
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, end of year
|
|
$
|
98,799
|
|
|
$
|
6,592
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these financial statements
F-8
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
For The Years Ending September 30, 2008 and 2007
NOTE 1 - NATURE OF BUSINESS
Hemagen Diagnostics, Inc. (the “Company”), a Delaware company, is a biotechnology company
that develops, manufactures, and markets more than 68 FDA-cleared proprietary medical diagnostic test kits. Hemagen has two different product lines. The Virgo
®
product line consists of
diagnostic test kits that are used to aid in the diagnosis of certain autoimmune and infectious diseases, using ELISA, Immunofluorescence, and hemagglutination technology. The Analyst
®
product line is an FDA-cleared clinical chemistry analyzer system, including consumables, that is used to measure important constituents in human and animal blood. In the United States, the Company sells its products through distributors and
directly to physicians, veterinarians, clinical laboratories and blood banks and on a private-label basis through multinational distributors. Internationally, the Company sells its products primarily through distributors. The Company was
incorporated in 1985 and became a public company in 1993.
NOTE 2 - FINANCIAL CONDITION
At September 30, 2008, Hemagen had $98,799 of unrestricted cash, negative working capital of $2,225,607 and a current ratio of .6 to 1.0. Hemagen
currently has a revolving line of credit with a bank for the purpose of financing working capital needs as required. The line of credit currently provides for borrowings up to $500,000, at an annual interest rate of the prime rate plus 3/4%.
Hemagen believes that cash flow from operations and cash on hand at September 30 will be sufficient to finance its operations for
fiscal 2009. The line of credit matures on March 31, 2009 and the Company expects to renew the line at that time. However, Hemagen can give no assurances that it will have sufficient cash to repay the line of credit if it is not renewed or
finance its operations. Hemagen has no off-balance sheet financing arrangements.
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company, it’s wholly owned subsidiaries, Reagents Applications, Inc. (“RAI”) and Hemagen Diagnostics Commercio,
Importaco & Exporataco, Ltd. (“HDC”). All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
F-9
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES - continued
Foreign Currency Translation
The financial position and results of operations of HDC are measured using HDC’s local currency as the functional currency. Revenues and expenses of HDC have been translated into U.S.
dollars at average exchange rates prevailing during the year. Assets and liabilities have been translated at the rates of exchange on the balance sheet date. The resulting translation gain and loss adjustments are recorded directly as a separate
component of stockholders’ equity.
Cash Equivalents
The Company considers all investments with original maturities of three months or less at the date of purchase to be cash equivalents. The Company may have amounts in cash accounts in excess of
federally-insured limits throughout the year.
Accounts Receivable
A majority of the Company’s accounts receivable are due from distributors (domestic and international), hospitals, universities, and physician and veterinary offices and other entities in
the medical field. Credit is extended based on evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are stated at amounts due from customers net of an allowance for doubtful accounts.
Accounts that are outstanding longer than the contractual payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due, the
Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a whole. The Company writes-off accounts receivable when they become
uncollectible, and payments subsequently received on such receivables are posted against the allowance for doubtful accounts. The balance of the allowance for doubtful accounts was $62,485 and $51,316 on September 30, 2008 and 2007,
respectively. The Company does not accrue interest on accounts receivable past due.
Inventories
Inventories are stated at the lower of cost or market, determined on a first-in, first-out basis. Inventory reserves are established for obsolescence
based on expiration dating of perishable products and excess levels of inventory on hand. The Company had $526,716 and $599,836 of inventory reserves as of September 30, 2008 and 2007, respectively. The $526,716 reserve as of September 30,
2008 included approximately $330,000 of reserves related to old Analyst equipment and parts that are not expected to be utilized within the next twelve months.
F-10
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES - continued
Long-lived Assets
The Company reviews the carrying values of its long-lived assets for possible impairment annually or whenever events or changes in circumstances indicate that the carrying amount of the assets
may not be recoverable. If the review indicates that long-lived assets are not recoverable (i.e., the carrying amount is less than the future projected undiscounted cash flows), the carrying amount would be reduced to fair value and a charge to
income would be recorded.
Property and Equipment
Property and equipment is stated at net book value. Depreciation is provided on a straight-line basis over the estimated useful lives of the related assets, which range from 3 to 10 years.
Expenditures for repairs and maintenance are expensed as incurred.
Other Assets
Other assets, net at September 30, 2008 and 2007 consists of product registration certificates that are being amortized over their 5 year life,
security deposits relating to the facilities that are being leased and the long term portion of the Note Receivable
Income Taxes
The Company follows the liability method of accounting for income taxes. Under this method, deferred tax liabilities and assets are
recognized for the expected future tax consequences of temporary differences between the carrying amount and the tax basis of assets and liabilities at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in
which the differences are expected to affect taxable income. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
Assets Held for Sale
Assets held for sale as of September 30, 2007
represents the net book value of property and equipment that resided in the Company’s San Diego facility that were held for sale as of September 30, 2007. These assets were sold on October 8, 2007.
Revenue Recognition
Revenues
from the sale of products are recognized when shipped, all contractual obligations have been satisfied, and the collection of the resulting receivable is reasonably assured. Revenues from product service contracts, which are based on their relative
fair value, are recognized ratably over the term of the contract. Losses are provided for at the time that management determines that contract costs will exceed related revenues. The portion of product service contracts not complete at the balance
sheet date is included in deferred revenue.
F-11
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES - continued
Stock- Based Compensation
At September 30, 2008, options for the purchase of 2,464,014 shares of common stock with a weighted average exercise price of $1.05 were outstanding. During the twelve months ended
September 30, 2008, options to purchase 247,000 shares at an exercise price of $.22 per share were granted. During the twelve months ended September 30, 2008, no options were exercised and 72,500 options expired or were forfeited.
Under SFAS No. 123R, we have elected to use the Black-Scholes option pricing model to determine the fair value of our awards on the
date of grant. The fair value of each option award is estimated on the date of grant using a Black-Scholes option-pricing formula that uses the assumptions noted in the table and discussion that follows:
|
|
|
|
|
|
|
|
|
Period Ending
September 30,
|
|
|
|
2008
|
|
2007
|
|
Dividend yield
|
|
—
|
|
—
|
|
Expected volatility
|
|
95% - 114%
|
|
82%
|
|
Risk-free interest rate
|
|
2.46% - 3.16%
|
|
4%
|
|
Expected life in years
|
|
5-10
|
|
5-10
|
We will reconsider the use of the Black-Scholes model if additional information becomes available
in the future that indicates another model would be more appropriate, or if grants issued in future periods have characteristics that cannot be reasonably estimated under this model.
We have elected to continue straight-line amortization of stock-based compensation expense over the requisite service period. Prior to the adoption of SFAS No. 123R, we recognized the effect
of forfeitures in our pro forma disclosures as they occurred. In accordance with the new standard, we have estimated forfeitures and are only recording expense on shares we expect to vest.
As of September 30, 2008, there was $22,480 of unrecognized compensation cost related to share-based compensation arrangements that we expect to vest. This cost will be fully amortized
within 5 years. The options exercisable as of September 30, 2008 have no intrinsic value. All options granted have the same exercise price as the stock price on the date the options were granted.
Research and Development Costs
All costs incurred to research, design and develop products are considered research and development costs and are charged to expense as incurred.
F-12
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES - continued
Fair Value of Financial Instruments
Financial instruments include cash and cash equivalents, short-term investments, customer receivables, accounts payable, certain other accrued liabilities
and long-term debt. The fair value of long-term debt approximates the carrying amount based on the current rate offered to the Company for debt of similar remaining maturities. The carrying values of all other financial instruments are reasonable
estimates of their values.
Advertising Expenses
Costs of advertising, which also include promotional expenses, are expensed as incurred. Advertising expenses for fiscal 2008 and 2007 were $20,255 and $10,545, respectively.
Shipping and Handling
The
cost of shipping products to customers is included in cost of goods sold. Amounts billed to a customer in a sale transaction related to shipping and handling is classified as revenue.
NOTE 4 - RELATED PARTY TRANSACTIONS
William P. Hales, the Chairman of the
Board of Directors and President and Chief Executive Officer of the Company owns $768,000 face value of the senior subordinated secured convertible notes due September 30, 2009. Refer to Note 11 for a description of the senior notes.
NOTE 5 - INVENTORIES
Inventories at September 30, consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Raw materials
|
|
$
|
1,385,253
|
|
|
$
|
1,510,204
|
|
|
Work-in-process
|
|
|
159,903
|
|
|
|
163,218
|
|
|
Finished goods
|
|
|
1,018,609
|
|
|
|
1,481,295
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,563,765
|
|
|
|
3,154,717
|
|
|
Less reserves
|
|
|
(526,716
|
)
|
|
|
(599,836
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Inventories, net
|
|
$
|
2,037,049
|
|
|
$
|
2,554,881
|
|
|
|
|
|
|
|
|
|
|
|
F-13
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 6 - PROPERTY AND EQUIPMENT
Property and equipment at September 30, consists of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Furniture and equipment
|
|
$
|
6,591,249
|
|
|
$
|
6,029,352
|
|
|
Leasehold improvements
|
|
|
76,326
|
|
|
|
76,499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,667,575
|
|
|
|
6,105,851
|
|
|
Less accumulated depreciation and amortization
|
|
|
(5,970,504
|
)
|
|
|
(5,883,861
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
697,071
|
|
|
$
|
221,990
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization expense relating to property and equipment was $107,552 and $36,016
for the years ended September 30, 2008 and 2007, respectively.
NOTE 7 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
Accounts payable and accrued liabilities include the following at September 30:
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
2007
|
|
Accounts payable – trade
|
|
$
|
735,516
|
|
$
|
854,495
|
|
Accrued professional fees
|
|
|
28,129
|
|
|
80,280
|
|
Accrued vacation
|
|
|
98,412
|
|
|
130,137
|
|
Accrued other
|
|
|
265,542
|
|
|
267,390
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
1,127,599
|
|
$
|
1,332,302
|
|
|
|
|
|
|
|
|
NOTE 8 - DEVELOPMENT AND LICENSE AGREEMENTS
In August 1998, the Company entered into an agreement under which the Company obtained exclusive proprietary rights to certain patents, licenses and
technology to manufacture market and sell certain products. This agreement required quarterly royalty payments based on a percentage of sales of defined products through August 31, 2004.
In addition, the Company entered into a sublicense agreement whereby two license agreements
related to certain Analyst
®
products, one of which expired in March 2000, were transferred to the Company. The remaining license agreement, which contains provisions for royalty
obligations, based on production and net sales of certain products, expired in February 2007.
F-14
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 8 - DEVELOPMENT AND LICENSE AGREEMENTS -
continued
There was no expense recorded under the royalty agreements in 2008 or 2007. During 2007, management
determined that the royalty accrual was unlikely to be paid and therefore adjusted the accrual accordingly.
NOTE 9 - LINE OF CREDIT
In September 2002, the Company obtained a revolving line of credit with a bank
for the purpose of financing working capital needs as required. The line of credit facility renews each year on March 31 and provides for borrowing up to $500,000 at an interest rate of Prime Rate plus
3
/
4
%. The rate as of September 30, 2008 was 5.75%. Maximum borrowings under the loan are based on the domestic receivables and
inventory of the Company. The line of credit facility has a first lien on all assets of the Company. At September 30, 2008 and 2007, the outstanding balance was $500,000 and $340,000 on the line of credit, respectively. The line expires on
March 31, 2009. The Company was in compliance with its bank covenants as of September 30, 2008 and obtained a waiver for non-compliance for the period ending September 30, 2007.
NOTE 10 - NOTE PAYABLE
As of
September 30, 2008, Hemagen Diagnostics Commercio, Importaco & Exporataco, Ltd. (“HDC”) had arranged financing with Itau Bank to finance the purchase of automated equipment to be placed into key customer accounts. As of
September 30, 2008, the Company had outstanding borrowings on this note in the amount of $288,292 Reals. These loans bear interest at 1.45% per month or 17.4% annual interest, and are repaid in 24 equal monthly installments. These capital
loans are secured by HDC receivables at the ratio of 50% receivable to loan value. The outstanding balance on the loans as of September 30, 2008 was $151,724 and $35,588 as of September 30, 2007. Future minimum principal payments on these
notes over the next five years are as follows:
|
|
|
|
|
|
Years ending September 30,
|
|
|
|
2009
|
|
$
|
32,257
|
|
2010
|
|
$
|
119,467
|
|
2011
|
|
|
—
|
NOTE 11 - EXCHANGE OFFERING
In December 2004, the Company completed an exchange offering of its senior subordinated secured convertible notes due on April 17, 2005 (“Old Notes”) for 5,079,438 shares of its
common stock and $4,033,225 of senior subordinated secured convertible notes due on September 30, 2009 (“New Notes”). At the completion of the exchange offering, $6,065,000 of Old Notes, all but $25,000 of the Old Notes, representing
over 99% of the Old Notes had been exchanged. The exchange offering was effective as of September 30, 2004, since at that time more than 80% of the Old Notes had been tendered for exchange. The Company has accounted for the exchange offering as
though the exchange of the entire amount of $6,065,000 of Old Notes was effective as of September 30, 2004, because at September 30, 2004 the Company had the right and the intent to require the remaining Old Notes to be exchanged
F-15
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 11 - EXCHANGE OFFERING - continued
since more than 75% in value and 50% in number of the Old Notes had been tendered. In December 2005, the Company exchanged the remaining $25,000 of notes for
a New Note with a face value of $16,625 and original issue discount of $1,047 and 20,938 shares of common stock. The investor converted under the same terms as those that had accepted the exchange effective September 30, 2004 and was accounted
for as if it had been converted at that time.
The shares of common stock issued in connection with the exchange offering were restricted
by the terms of the exchange offer from sale or transfer until after September 30, 2005.
The New Notes pay interest quarterly at an
annual rate of 8%, are convertible at the option of the holder at $0.75 per share into shares of the Company’s common stock and mature on September 30, 2009. The New Notes are secured by a first lien on all real, tangible and intangible
property except that the terms of the New Notes provide that the following are subordinated to the security for the New Notes: the $25,000 of Old Notes; up to a maximum of $3 million credit facility; real estate financing obtained for a corporate
headquarters subject to limitation; and up to $4.0 million for financing related to strategic acquisitions. The Company has the right to require conversion of the New Notes at any time if the Company’s common stock has traded at or above $1.25
per share for a consecutive twenty-day trading period. The Company may also prepay the New Notes at any time at their full face amount plus any accrued and unpaid interest.
The Company determined the fair value of the 5,079,438 shares of its common stock on the closing market price, at September 30, 2004, of $0.38 to be $1,930,186. The fair value of the New
Notes was determined by management based on a 10% discount rate, resulting in a fair value of the New Notes of $3,706,362. In connection with the exchange offering at September 30, 2004 the Company expensed $863,253 of the $1,291,705 debt
discount remaining at the time of the exchange offering related to the Old Notes. The amount recorded as expense represented the excess of the fair value of the New Notes and common stock issued in the exchange offering over the net book value of
the Old Notes. At September 30, 2008 and 2007 the unamortized discount on these notes was $70,587 and $143,575, respectively.
NOTE
12 - STOCKHOLDERS’ EQUITY
Preferred Stock
The Company is authorized to issue up to 1,000,000 shares of preferred stock, $.01 par value per share. The preferred stock may be issued in one or more series, the terms of which may be
determined at the time of issuance by the Board of Directors and may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights and sinking fund provisions. No shares of preferred stock have been issued.
F-16
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 12 - STOCKHOLDERS’ EQUITY - continued
Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss consists solely of foreign currency translation adjustments totaling $100,090 and $48,530 at September 30, 2008
and 2007, respectively.
Stock Options
On April 25, 2007, the shareholders voted to approve the 2007 Stock Option Plan. Under this plan, the Board has reserved a maximum of 1,500,000 shares for issuance pursuant to stock options, stock appreciation
rights, restricted stock awards, restricted stock units and stock awards.
On February 27, 2001, the shareholders voted to approve the
2001 Stock Option Plan. The 2001 Stock Option Plan provides for the grant of incentive and nonqualified stock options for the purchase of an aggregate of 1,000,000 shares of the Company’s common stock by employees, directors and consultants of
the Company.
The Compensation Committee of the Board of Directors is responsible for the administration of both Plans. The Compensation
Committee determines the term of each option, the number of shares for which each option is granted and the rate at which each option is exercisable.
Changes in options outstanding are summarized as follows:
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
Weighted-
Average
Exercise
Price
|
|
Balance, October 1, 2006
|
|
2,481,014
|
|
|
$
|
1.08
|
|
Granted
|
|
117,500
|
|
|
|
0.24
|
|
Exercised
|
|
—
|
|
|
|
—
|
|
Cancelled or expired
|
|
(309,000
|
)
|
|
|
0.58
|
|
|
|
|
|
|
|
|
|
Balance, September 30, 2007
|
|
2,289,514
|
|
|
$
|
1.11
|
|
Granted
|
|
247,000
|
|
|
|
0.22
|
|
Exercised
|
|
—
|
|
|
|
—
|
|
Cancelled or expired
|
|
(72,500
|
)
|
|
|
0.24
|
|
|
|
|
|
|
|
|
|
Balance, September 30, 2008
|
|
2,464,014
|
|
|
|
1.05
|
|
|
|
|
|
|
|
|
|
Exercisable at September 30, 2008
|
|
2,279,014
|
|
|
$
|
1.11
|
|
|
|
|
|
|
|
|
F-17
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 12 - STOCKHOLDERS’ EQUITY - continued
The following table summarizes information about stock options outstanding at September 30,
2008:
|
|
|
|
|
|
|
|
|
Options Outstanding
|
|
Range of Exercise
Prices
|
|
Number
Outstanding
at September 30,
2008
|
|
Weighted-
Average
Remaining
Contractual
Life (years)
|
|
Weighted
Average
Exercise
Price
|
|
0.14 – 0.19
|
|
167,000
|
|
6.0
|
|
0.17
|
|
0.20 – 0.34
|
|
360,000
|
|
6.4
|
|
0.21
|
|
0.35 – 0.77
|
|
185,000
|
|
3.9
|
|
0.51
|
|
0.78 – 0.97
|
|
20,000
|
|
3.4
|
|
0.97
|
|
0.98 – 1.36
|
|
1,732,014
|
|
1.0
|
|
1.36
|
|
|
|
|
|
|
|
|
|
0.14 – 1.36
|
|
2,464,014
|
|
2.4
|
|
1.05
|
The fair value of each option grant was determined on the date of the grant using the
Black-Scholes option-pricing model with the following weighed-average assumptions used for grants in 2008 and 2007;
|
|
|
|
|
|
|
|
|
|
2008
|
|
2007
|
|
|
Dividend yield
|
|
—
|
|
—
|
|
|
Expected volatility
|
|
95% - 114%
|
|
82
|
%
|
|
Risk-free interest rate
|
|
2.46% - 3.16%
|
|
4
|
%
|
|
Expected life in years
|
|
5 -10
|
|
5-10
|
|
The weighted average grant date fair value of options granted during 2008 and 2007 was $28,484 and
$15,384, respectively.
Stock Rights Purchase Agreement
In fiscal year 1999, the Company’s Board of Directors implemented a Stock Purchase Rights Agreement (the “Agreement”). Under the Agreement, as amended, the Company declared a
dividend of one common share purchase right (a “Right”) for each share of the Company’s outstanding common stock as of February 10, 1999. Each Right entitles the holder to purchase from the Company $4.00 worth of Company common
stock at a per-share price equal to 50 percent of the current market price. The Rights become exercisable only if a person or group, as defined in Section 13(d)(3) of Securities Exchange Act of 1934, as amended, acquires beneficial ownership of
15 percent or more of the Company’s outstanding common stock or announces a tender offer that would result in beneficial ownership of 15 percent or more of the Company’s outstanding common stock. Pursuant to a Board of Directors’
resolution dated January 9, 2003, William P. Hales, the Company’s current Chief Executive Officer and a stock and debt holder, is exempt under the Agreement. The Rights, which expire on January 27, 2009, are redeemable in whole, but
not in part, at the Company’s option at $0.001 per Right at any time prior to the earlier of ten days after public announcement that a person or group has acquired beneficial ownership of 15% or more of the Company’s outstanding common
stock or the expiration date of the Rights. No rights have been exercised as of September 30, 2008 or 2007.
F-18
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 13 - INCOME TAXES
For the years ended September 30, 2008 and 2007, domestic and foreign (losses) or income before income taxes from continuing operations are as follows:
|
|
|
|
|
|
|
|
|
|
|
Years ended September 30,
|
|
2008
|
|
|
2007
|
|
|
Domestic
|
|
$
|
(680,133
|
)
|
|
$
|
(503,117
|
)
|
|
Foreign
|
|
|
447,798
|
|
|
|
238,827
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from continuing operations, before income taxes
|
|
$
|
(232,335
|
)
|
|
$
|
(264,293
|
)
|
|
|
|
|
|
|
|
|
|
|
For the fiscal years ended September 30, 2008 and 2007, the Company had current income tax
expense of $129,333 and $47,515 respectively which related to foreign income tax expenses from its Brazilian subsidiary.
The difference
between income taxes on continuing operations provided at the Company’s effective tax rate and the Federal statutory rate is as follows:
|
|
|
|
|
|
|
|
|
Years ended September 30,
|
|
2008
|
|
|
2007
|
|
|
Federal tax at statutory rate
|
|
34
|
%
|
|
34
|
%
|
|
Valuation Allowance
|
|
(34
|
)
|
|
(34
|
)
|
|
Current tax benefit of operating losses
|
|
—
|
|
|
—
|
|
|
Impact of international operations
|
|
29.0
|
|
|
18.0
|
|
|
|
|
|
|
|
|
|
|
|
|
29.0
|
%
|
|
18.0
|
%
|
|
|
|
|
|
|
|
|
Deferred tax assets (liabilities) are comprised of the following at September 30, 2008 and
2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Net operating loss carry forwards
|
|
$
|
6,947,000
|
|
|
$
|
7,021,000
|
|
|
Inventory reserve
|
|
|
203,000
|
|
|
|
240,000
|
|
|
Accounts receivable reserve
|
|
|
13,000
|
|
|
|
21,000
|
|
|
Debt conversion cost
|
|
|
69,000
|
|
|
|
138,000
|
|
|
Other
|
|
|
56,000
|
|
|
|
97,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Total deferred tax assets
|
|
|
7,288,000
|
|
|
|
7,517,000
|
|
|
Basis difference in fixed assets
|
|
|
18,000
|
|
|
|
(15,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
|
7,306,000
|
|
|
|
7,502,000
|
|
|
Valuation allowance
|
|
|
(7,306,000
|
)
|
|
|
(7,502,000
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
The Company has provided a valuation allowance equal to 100% of the net deferred tax asset in
recognition of the uncertainty regarding the ultimate amount of the net deferred tax asset that will be realized.
F-19
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 13 - INCOME TAXES - continued
At September 30, 2008 the Company had approximately $20,432,000 of federal operating loss
carry-forwards, respectively, available to offset future taxable income, which expire on various dates through 2026. Ownership changes as defined in the Internal Revenue Code may limit the amount of net operating loss and tax credit carry-forwards
that may be utilized annually. The Company also had Brazilian net operating loss carry-forwards of approximately $750,000 available to offset future Brazilian taxable income.
NOTE 14 - SIGNIFICANT SALES AND CONCENTRATION OF CREDIT RISK
Revenues derived
from export sales, from continuing operations, amounted to approximately $2,021,000, or 32% of total sales in 2008 and $2,352,000, or 52% of total sales in 2007. Export sales to Europe were approximately $620,000 or 10% of total sales in 2008 and
$621,000 or 13% of total sales in 2007. Sales to the Company’s Brazilian subsidiary, which are eliminated in the consolidated financial statements, were approximately $1,030,000 and $624,000 in 2008 and 2007, respectively.
At September 30, 2008 and 2007, the Company had approximately $89,600 and $64,600 of cash in foreign bank accounts.
NOTE 15 - GEOGRAPHICAL INFORMATION
The Company considers its manufactured kits, tests and instruments as one operating segment, as defined under Statement of Financial Accounting Standards No. 131 “Disclosures about Segments of an Enterprise and Related
Information.”
The following table sets forth revenue and assets, for continuing operations, by geographic location.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United*
States
|
|
Brazil
|
|
Consolidated
|
|
September 30, 2008:
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
3,881,199
|
|
$
|
2,493,600
|
|
$
|
6,374,799
|
|
Long-lived assets
|
|
|
698,139
|
|
|
466,657
|
|
|
1,164,796
|
|
September 30, 2007:
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
|
3,116,649
|
|
$
|
1,370,587
|
|
$
|
4,487,236
|
|
Long-lived assets
|
|
|
160,094
|
|
|
142,056
|
|
|
302,150
|
|
*
|
Includes export sales to countries other than Brazil of approximately $992,000 and $981,000 in 2008 and 2007, respectively.
|
Long-lived assets includes property and equipment, intangibles, and the long-term portion of the Note Receivable, net of any depreciation and
amortization.
F-20
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 16 - COMMITMENTS
The Company leases certain facilities and equipment under non-cancelable operating leases lasting through 2012. Future minimum lease commitments under the non-cancelable operating leases are as
follows:
|
|
|
|
|
|
Years ending September 30,
|
|
|
|
2009
|
|
$
|
210,645
|
|
2010
|
|
|
171,773
|
|
2011
|
|
|
176,782
|
|
2012
|
|
|
134,261
|
|
2013
|
|
|
—
|
Rent expense from continuing operations was approximately $356,000 and $308,000 for 2008 and 2007,
respectively.
Retirement and Directors Plan
The Company maintains a defined contribution retirement plan, which qualifies under Section 401(k) of the Internal Revenue Code, covering substantially all employees. Participant contributions and employer
matching contributions are made as defined in the 401(k) Plan agreement. No Company contributions were made to the 401(k) Plan in fiscal years 2008 and 2007.
The Company maintains a rule 10b5-1 Stock Purchase Plan (the 10b5-1 Plan) for its non-employee Directors. Non-employee Directors are paid $3,500 per quarter of the total, $1,500 is paid in cash and $2,000 is
contributed to the 10b5-1 Plan and is used to purchase Company stock by the 10b5-1 Plan in the open market. Commencing October 1, 2008, the Directors compensation changed and the Directors will be paid $2,500 per quarter and will receive 5,000
shares per quarter of Hemagen stock.
Effective October 1, 2003, the Company created an Employee Stock Ownership Plan (ESOP) for the
benefit of its employees, which has been determined by the Internal Revenue Service to be a qualified retirement plan subject to section 4975(E)7 of the Code. The Company’s contributions to the ESOP were cash of $40,000 in each of fiscal 2008
and 2007. At September 30, 2008 and 2007, the ESOP owned approximately 448,666 shares and 360,182 shares of Hemagen common stock, respectively, that were purchased in the open market by the ESOP.
NOTE 17 - NET LOSS PER SHARE OF COMMON STOCK
Basic earnings per share excludes the effect of any dilutive options or convertible securities and is computed by dividing the net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings
per share are computed by dividing the net income (loss) by the sum of the weighted average number of common shares and common share equivalents outstanding, unless the impact of those equivalents is antidilutive. The computation of weighted average
shares outstanding for fiscal years 2008 and 2007 is as follows:
|
|
|
|
|
|
|
|
|
2008
|
|
2007
|
|
Common shares outstanding for basic EPS
|
|
15,225,289
|
|
15,225,289
|
|
Shares issued upon assumed exercise of outstanding stock options
|
|
4,545
|
|
—
|
|
|
|
|
|
|
|
Weighted average number of common and common equivalent shares outstanding for diluted EPS
|
|
15,229,834
|
|
15,225,289
|
|
|
|
|
|
|
F-21
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 17 - NET LOSS PER SHARE OF COMMON STOCK -
continued
Common share equivalents outstanding at September 30, 2008 and 2007 totaling 7,863,814 and
7,541,814 shares, respectively, including currently outstanding stock options and convertible debt, were not included in the denominator for diluted income per share as their effect was anti-dilutive.
NOTE 18 - DISCONTINUED OPERATIONS
During the year the Company sold the assets of its wholly-owed subsidiary Reagents Applications, Inc. The sale was consummated on October 8, 2007. The results of the operations for this division have been presented as discontinued
operations in the accompanying financial statements for the periods ending September 30, 2008 and September 30, 2007.
Results
from discontinued operations, net of income tax, for the periods ending September 30, 2008 and 2007 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
2008
|
|
|
2007
|
|
|
Net sales
|
|
$
|
497,509
|
|
|
$
|
2,114,586
|
|
|
Costs of sales
|
|
|
546,566
|
|
|
|
2,037,117
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit
|
|
|
(49,057
|
)
|
|
|
77,469
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
243,528
|
|
|
|
365,240
|
|
|
Research and development
|
|
|
1,708
|
|
|
|
271,021
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating costs and expenses
|
|
|
245,236
|
|
|
|
636,261
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(294,293
|
)
|
|
|
(558,792
|
)
|
|
Other income (expenses):
|
|
|
|
|
|
|
|
|
|
Interest Income (net)
|
|
|
—
|
|
|
|
20,670
|
|
|
Other Income (expense)
|
|
|
—
|
|
|
|
(1
|
)
|
|
Gain on Sale of Assets
|
|
|
1,094,817
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
1,094,817
|
|
|
|
20,669
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) before income taxes
|
|
|
800,524
|
|
|
|
(538,123
|
)
|
|
Income Tax
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from discontinued operations
|
|
$
|
800,524
|
|
|
$
|
(538,123
|
)
|
|
|
|
|
|
|
|
|
|
|
F-22
Hemagen Diagnostics, Inc. and Subsidiaries
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS-CONTINUED
For The Years Ending September 30, 2008 and 2007
NOTE 18 - DISCONTINUED OPERATIONS - continued
Cost of sales during 2008 includes approximately $49,000 of additional reserves recorded for
remaining Raichem inventory being sold under an Inventory Purchase Agreement. In the Inventory Purchase Agreement the Company agreed to sell the inventory from this division to the purchaser at cost, less any overhead charges. The Company had to
write-down the value of the inventory by approximately $147,000 due to this agreement and this write-down is included in cost of sales for 2007. Selling and general administrative expenses for 2008 included rent owed under a lease agreement that
expired in May 2008, legal fees associated with the sale of Raichem and facility related shut-down expenses.
NOTE 19 - SUPPLEMENTAL
DISCLOSURE OF CASH
|
|
|
|
|
|
|
|
|
September 30,
|
|
2008
|
|
2007
|
|
Cash paid for interest
|
|
$
|
364,275
|
|
$
|
343,604
|
|
|
|
|
|
|
|
|
|
Cash paid for income taxes (Brazil)
|
|
$
|
129,333
|
|
$
|
47,515
|
|
Total PP&E purchases
|
|
$
|
606,735
|
|
$
|
85,864
|
|
Financed portion of equipment purchases
|
|
|
238,298
|
|
|
34,588
|
|
|
|
|
|
|
|
|
|
Cash paid for PP&E purchases
|
|
$
|
368,437
|
|
$
|
51,276
|
|
|
|
|
|
|
|
|
F-23
Hemagen Diagnostics (CE) (USOTC:HMGN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Hemagen Diagnostics (CE) (USOTC:HMGN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
